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ABSTRACT 
Background: Despite of the amount of work on the meningococcal serogroup B bacteria and 
immunity to disease caused by them, a satisfactory vaccine for these important pathogens is 
still missing. Several group B meningococcal vaccines based on outer membrane protein 
vesicles (OMV) or complexes have been evaluated in phase II and III clinical trials. Although 
the antibody responses in connection with these phase III clinical protection trials and 
separate immunogenicity trials have been analyzed extensively by enzyme immunosorbent 
assay (EIA) and by assays for serum bactericidal (SBA) and opsonophagocidal activity, the 
specificity and the functional activity of antibodies providing protection against serogroup B 
disease is still partly open. The lack of reliable laboratory correlates or surrogates for 
protection has hampered vaccine development against this important pathogen.  
Study aims: The main aim of the present study was evaluate the applicability of an infant rat 
protective activity (IRPA) assay to assess meningococcal serogroup B OMV vaccine 
responses induced in humans. To this end, pre- and post-vaccination serum samples from 
teenagers immunized with two doses of either the Norwegian OMV vaccine (MenBvac™), 
the Cuban OMV vaccine (VA-MENGOC-BC™), or the serogroup A/C capsular PS control 
vaccine during a previous immunogenicity trial in Iceland were analyzed for IRPA, and the 
results compared to SBA and EIA data obtained with the same serum set and vaccine efficacy 
data obtained earlier in different study populations. We also studied the specificity and 
functional activity of natural antibodies conferring protection in this animal model. Well-
characterized Mabs were used to assess the influence of antibody specificity and isotype on 
protection, and complement component C6 deficient animals to evaluate the importance of 
complement-mediated bacterial lysis on protection. 
Results and conclusions: As compared to the results from rises in anti-OMV IgG levels 
measured by EIA and to a lesser extent also in SBA titres, the numbers of vaccine responders 
detected in IRPA assay were only modest. Thus, although likely to be useful for the pre-
clinical evaluation of candidate MenB vaccines, the IRPA assay, as described herein, is 
probably less suitable for large-scale evaluation of serogroup B OMV vaccine responses in 
clinical samples. Despite this limitation, the IRPA assay seemed to give some additional value 
over the SBA assay in that many SBA negative pre-vaccination sera were often IRPA positive 
though many SBA positive sera remained IRPA negative. In sera taken before vaccination the 
IRPA against strain 44/76-SL was mainly mediated by serogroup B capsular specific IgM 
antibody and was independent of complement-mediated bacterial lysis as evident from the 
lack of SBA in vitro and equal protective activity of normal human sera in complement 
sufficient and C6 deficient animals. Studies with serogroup B capsular specific antibody of 
mouse origin confirmed the latter finding. These findings were in contrast to PorA protein 
specific IgG antibodies whose protective activity in C6 deficient animals was severely 
impaired. A clear connection between the acquisition of natural B-PS specific IgM antibodies 
and IRPA was also indicated. These results suggest that importance capsular PS specific 
antibodies on protective immunity against serogroup B disease may have been 
underestimated. 
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TIIVISTELMÄ 
Tausta: Tällä hetkellä ei ole olemassa tyydyttävää rokotetta B-ryhmän meningokokin 
aiheuttamia vakavia infektioita vastaan. Useita ulkokalvoproteiinirokotteita on kehitteillä ja 
näistä osan suojatehoa on jo tutkittu kliinisissä faasi II ja III kokeissa. Vaikka rokotteiden 
aikaansaamien vasta-aineiden määrällisiä ja laadullisia ominaisuuksia on tutkittu eri 
menetelmillä, kuten ELISA-menetelmällä, bakterisidia- ja fagosytoosi-testeillä, on suojaavien 
vasta-aineiden spesifiteetti sekä se, miten vasta-aineet aineet suojaavat B-ryhmän 
meningokokkitaudeilta, vielä osin selvittämättä. Kliinisen suojatehon laboratoriokorrelaatin 
puuttuminen on vaikeuttanut rokotekehitystyötä.  
Tavoitteet: Tämän tutkimuksen tarkoituksena oli selvittää, voidaanko rotanpoikasen 
suojatestiä käyttää B-ryhmän meningokokin ulkokalvoproteiinirokotteiden rokotteiden 
suojatehon mittaamiseen immunisoimalla rotanpoikaset passiivisesti ennen rokottamista ja 
rokotuksen jälkeen otetuilla ihmisseerumeilla, ja mittaamalla, kuinka hyvin ne suojaavat 
kokeelliselta meningokokki-infektiolta. Tutkimusrokotteina käytettiin norjalaista 
(MenBvac™) ja kuubalaista (VA-MENGOC-BC™) ulkokalvoproteiinirokotetta ja 
kontrollirokotteena meningokokin A/C-polysakkaridirokotetta. Näin saatuja suojatuloksia 
verrattiin ELISA- ja bakterisidia-testeillä saatuihin tuloksiin sekä tutkimusrokotteiden 
kliiniseen suojatehoon. Lisäksi tutkimme, mikä on rotanpoikasen infektiomallissa suojaavien 
luonnollisten vasta-aineiden spesifiteetti ja mahdolliset toimintamekanismit käyttäen apuna 
komplementin C6-komponentin suhteen puutteellisia eläimiä. Selvitimme myös, onko eri 
spesifiteetin omaavilla tai eri IgG alaluokan vasta-aineilla eroja niissä mekanismeissa, miten 
ne suojaavat kokeelliselta meningokokki-infektiolta.  
Tulokset ja johtopäätökset: ELISA- ja bakterisidia-testiin verrattuna rotanpoikasen 
suojatestin kyky mitata rokotevasteita jäi alhaiseksi. Näin ollen se ei näytä soveltuvan 
sellaisenaan rokotteiden suojatehon arvioimiseen. Sen sijaan se näytti antavan lisäarvoa 
bakterisidia-testiin verrattuna siinä, että monet bakterisidia-testissä negatiiviset näytteet 
osoittautuivat rotanpoikasen suojatestissä positiivisiksi, joskin päinvastaistakin havaittiin. 
Kun ennen rokottamista otettuja seerumeja tutkittiin tarkemmin, havaittiin, että niiden antama 
suojavaikutus rotanpoikasen suojatestissä oli B-ryhmän meningokokin kapselia vastaan 
olevien IgM-luokan vasta-aineiden välittämää. Tämä suoja-vaikutus näytti olevan 
riippumatonta vasta-aineiden aikaansaamasta, komplementin välittämästä bakteerien 
hajoamisesta koska osa suojaavista ihmisten seerumeista jäi bakterisidia-testeissä 
negatiivisiksi. Normaaliseerumit myös suojasivat yhtä hyvin niin komplementin suhteen 
normaaleissa kuin komplementin C6-komponentin suhteen puutteellisissa eläimissä. Tämä 
havainto vahvistettiin hiirestä peräisin olevalla kapseli vasta-aineella, joka toisin kuin testatut 
eri IgG alaluokkien PorA-proteiini vasta-aineet suojasi niin komplementin suhteen normaalit 
kuin C6-puutteelliset rotat kokeelliselta taudilta. Osoitimme myös ajallisen yhteyden 
luonnollisten kapseli-vasta-aineiden kehittymisen ja rotanpoikasen suojamallissa mitattavan 
suojan välillä. Nämä tulokset viittaavat siihen, että luonnollisilla kapseli vasta-aineilla saattaa 
olla tärkeä rooli puolustuksessa myös B-ryhmän meningokokkitauteja vastaan, toisin kuin on 
tähän asti yleisesti ajateltu. 
Avainsanat: Neisseria meningitidis B, ulkokalvoproteiinirokotteet, rotanpoikasen 
infektiomalli 
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ABBREVIATIONS 
Ab  Antibody 
Al-B-PS Aluminum hydroxide gel-bound B-PS  
Al-C-PS Aluminum hydroxide gel-bound C-PS  
BA  Bactericidal activity 
B-PS  Group B polysaccharide 
CDC  Centers for Disease Control and Prevention 
CEACAM Carcinoembryonic antigen-related cell adhesion molecule 
cfu  Colony forming unit 
CI  Confidence interval 
C-PS  Group C polysaccharide 
CR  Complement receptor 
CSF  Cerebrospinal fluid 
CV  Coefficient of variation 
EIA  Enzyme immunoassay 
FbpA  Ferric binding protein A 
FcR  Receptor for Fc portion of immunoglobulins 
GM  Geometric mean  
GMC  Geometric mean concentration 
HmbR  Hemoglobin-binding OMP 
HMW  High molecular weight 
IAV  Influenzae A virus 
Ig  Immunoglobulin 
IgA  Immunoglobulin class A 
IgD  Immunoglobulin class D 
IgE  Immunoglobulin class E 
IgG  Immunoglobulin class G 
IgM  Immunoglobulin class M 
i.n.  Intranasal 
i.p.  Intraperitoneal 
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IRPA  Infant rat protective activity 
IT  Immunotype 
KTL  Kansanterveyslaitos (National Public Health Institute) 
LCCD  Late complement component deficiency 
LMW  Low molecular weight 
LNnT  Lacto-N-neotetraose 
LOS  Lipooligosaccharide 
Mab  Monoclonal antibody 
MAC  Membrane attack complex 
MCP  Membrane cofactor protein 
MLEE  Multilocus enzyme electrophoresis 
MLST  Multilocus sequence typing 
MV  Microvesicle 
NHS  Normal human serum 
NIBSC National Institute for Biological Standards and Control 
NIPH  Norwegian Institute of Public Health 
NspA  Neisserial surface protein A 
NVI  Netherlands Vaccine Institute 
O.D.  Optical density 
OM   Outer membrane 
OMP  Outer membrane protein 
OMV  Outer membrane vesicle 
Opa  Opacity protein 
OPA  Opsonophagocytic activity 
PI  Protection index 
PMNL  Polymorphonuclear leukocyte 
PorA  Porin A (class 1 OMP) 
PorB  Porin B (class 2/3 OMP) 
PS  Polysaccharide 
RB  Respiratory burst 
Rmp  Reduction modifiable protein (class 4 OMP) 
SBA  Serum bactericidal activity 
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SDS  Sodium dodecyl sulphate 
TbpA  Transferrin-binding protein A 
TbpB  Transferrin-binding protein B 
WBA  Whole blood assay 
VR  Variable region 
WRAIR Walter Reed Army Institute of Research 
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1 INTRODUCTION 
Meningococcal disease is one the most feared infections due to rapidity of onset, propensity 
to affect infants and young adults, high mortality, serious sequelae, and tendency to spread, 
sometimes globally. Though the causative organism, Neisseria meningitidis or 
meningococcus, can cause a spectrum of illnesses, two clinically overlapping syndromes, 
purulent meningitis and sepsis, are by far the most common and most serious presentations.  
Meningococci are divided into 12 serogroups on the basis of differences in the structure and 
antigenicity of their capsular polysaccharides (PSs). Serogroups A, B, and C account for 
approximately 90% of all cases of meningococcal disease worldwide, group B and C 
meningococci being the predominant causative agents in industrialized countries. Natural 
immunity against meningococcal disease develops with age, associated with an increase in 
serum bactericidal activity (SBA). Thus, induction of bactericidal antibodies has been 
regarded as evidence of the potential efficacy of putative vaccines. Indeed, because of the lack 
of an animal model, vaccine candidates considered promising on this basis have been directly 
subjected to efficacy trials in humans.  
Currently, there are capsular PS or conjugate vaccines to combat disease caused by serogroup 
A, C, Y and W135 meningococci, but no corresponding vaccine is available for serogroup B 
meningococci. This is due to poor immunogenicity of its capsular PS. Thus, vaccine research 
against serogroup B disease has focused on non-capsular antigens, mainly outer membrane 
proteins in the form of outer membrane vesicles (OMVs), or purified recombinant proteins, of 
which OMV vesicle vaccines have been evaluated in clinical efficacy trials. 
The development of serogroup B meningococcal vaccines has been hampered by the lack of 
reliable laboratory correlates or surrogates for protection. Although the antibody responses in 
connection with efficacy and separate immunogenicity trials have been analyzed extensively, 
there is still much uncertainty about the specificity and functional mechanisms of antibodies 
providing protection against serogroup B disease. In particular, despite the good predictive 
value of SBA for the protective efficacy of serogroup A and C capsular PS based vaccines the 
importance of SBA for protection against serogroup B disease remains partly open.  
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This thesis consists of a series of consecutive studies that have addressed the applicability of 
an infant rat model of serogroup B meningococcal infection for the assessment of 
meningococcal serogroup B OMV vaccine responses induced in humans. In the search for 
vaccine candidates capable of inducing SBA responses, natural immunity to serogroup B 
meningococcus has been less studied. Thus, the specificity and mechanisms of natural 
antibodies conferring protective activity to infant rats were also evaluated, and the importance 
of bacterial lysis on protection afforded by antibodies of different specificity or isotype 
assessed. 
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2 REVIEW OF LITERATURE 
2.1 Meningococcal disease 
2.1.1 The bacterium 
Neisseria meningitidis (the meningococcus) is an aerobic, gram-negative, non-motile, non-
sporulating coccus that occurs in pairs of cells (diplococcus). It is oxidase and catalase 
positive and produces acid from glucose and maltose.  
Of the genus of Neisseria, only N. gonorrhoea (the gonococcus) is always considered to be an 
invader in man, requiring eradication by chemotherapy. The other species occurring in man 
are regarded as more or less frequently isolated commensals, of which N. meningitidis is most 
often isolated from clinical samples and with gonococcus being the only species with 
potential to cause severe systemic disease in otherwise healthy individuals. N. lactamica
shares the nasopharyngeal colonization site with meningococci though they are not associated 
with invasive disease. Due to severity of meningococcal disease and especially the capability 
to epidemic spread, in most countries the notification of cases of systemic meningococcal 
disease to Public Health Authorities is obligatory. Together with collection and 
characterization of corresponding meningococcal isolates, clinical notifications form the basis 
for local, national and global epidemiology and disease control. 
Traditionally, the characterization of meningococcal strains has been based on bacterial 
phenotype, i.e. the recognition meningococcal surface structures by monoclonal or polyclonal 
antibodies raised in experimental animals (mice and rabbits) for these purposes. Thus, the 
antigenic variability of the capsular polysaccharide (PS) defines the serogroup, class 2/3 or 
porin B protein (PorB) the serotype, class 1 or porin A protein (PorA) the serosubtype, and 
lipooligosaccharide (LOS) the immunotype of a meningococcal strain (Frasch et al. 1985, 
Abdillahi and Poolman 1987). Due to the emergence of new PorB and especially PorA 
variants not recognized by currently available serotyping and serosubtyping reagents, DNA 
sequencing of variable regions of the respective porB and porA genes is currently replacing 
serological typing methods (Russell et al. 2004). Other molecular typing methods, indexing 
more slowly evolving variation in bacterial genome, namely multilocus enzyme 
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electrophoresis (MLEE) and more recently, multilocus sequence typing (MLST) (Maiden et 
al. 1998), are used to assign meningococcal strains into clonal complexes and have proven 
useful tools for long-term and global epidemiology.  
2.1.2 Epidemiology 
Meningococci are divided into 12 serogroups (A, B, C, H, I, K, L, W135, X, Y, Z, 29E) on 
the basis of differences in the structure and antigenicity of their capsular PS. Serogroups A, B, 
and C account for approximately 90% of all cases of meningococcal disease worldwide, 
group B and C meningococci being the predominant causative agents in industrialized 
countries. From an epidemiological perspective, meningococcal disease is a pleomorphic 
disease, with incidence rates, serogroup distribution, and the age groups most affected varying 
according to geographic location and time. 
It has been estimated that (excluding epidemics) approximately 500,000 cases of invasive 
meningococcal disease occur annually worldwide, with over 50,000 deaths (WHO 1998). In 
most countries, the annual attack rates vary from < 1 to 5 per 100,000 populations but may 
increase up to 1000 or more especially during serogroup A epidemics (WHO 1998). The 
disease is most common among infants and young children under 5 years of age, with a 
secondary smaller peak occurring among adolescents 15-19 years of age; approximately one-
third of the cases of sporadic meningococcal disease occur in adults >19 years of age (EU-
IBIS 2002). Epidemics tend to shift the age distribution, with older children, teenagers and 
young adults also affected (Peltola et al. 1982).  
The risk of epidemic disease differs between serogroups through mechanisms that are poorly 
understood. Serogroup A meningococcus has historically been the main cause of large 
epidemics and is still the dominating serogroup during both endemic and epidemic periods in 
sub-Saharan Africa in the so called African meningitis belt extending from Senegal in the 
west to Ethiopia in the east. In this area, epidemics caused mainly by serogroup A 
meningococci, and more recently serogroup W135 (Taha et al. 2002), occur in irregular 
cycles every 8 to 12 years, last for two to three dry seasons, fading away during the 
intervening rainy seasons (WHO 1998). Since the epidemic in Finland during 1973-74, 
serogroup A disease has been extremely rare in Europe though recently, a rise in the number 
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of cases of serogroup A meningococcal disease in Moscow has been reported (Lawrence and 
Handford 2003).  
Serogroup C typically causes smaller outbreaks or epidemics, and with serogroup B 
meningococcus is the prevalent cause of endemic disease in most industrialized countries. 
During last years, high or increasing proportions of group C strains, mainly belonging to 
hypervirulent ST-11/ET-37 clonal complex first identified in Canada in 1986 (Ashton et al.
1991), have been reported from several European countries including Belgium (De Schrijver 
and Maes 2003), the Czech republic (Krizova and Musilek 1995), the Netherlands (de Greeff
et al. 2003), Republic of Ireland (Fogarty 1997), Spain (Alcala et al. 2002) and the United 
Kingdom (Kaczmarski 1997, Ramsay et al. 1997). This lead to nationwide vaccination 
campaigns in several countries and the accelerated introduction of the newly developed 
serogroup C conjugate vaccine (Miller et al. 2001, de Greeff et al. 2003, De Schrijver and 
Maes 2003, Salleras et al. 2003).  
Serogroup B meningococci differ from serogroups A and C in disease epidemiology. In 
contrast to serogroup A and C epidemics, which usually resolve in 1 to 3 years, serogroup B 
epidemics begin more slowly, usually reach lower country-wide rates of 5 to 20 cases per 100 
000 population per year and may persist for 5 to 10 years or longer, as seen in past decades in 
Cuba (Sierra et al. 1991), Norway (Lystad and Aasen 1991), Brasilia (Sacchi et al. 1998a), 
areas of Chile (Cruz et al. 1990), and more recently, in New Zealand (Baker et al. 2001).  
2.1.3 Carriage
It has been estimated that approximately 10% of the population carry meningococci in their 
nasopharynx (Cartwright et al. 1987); yet only a minority of carriers develop invasive disease. 
Carriage is most common in young adults, less so in young children and relatively rare in 
adult populations (Cartwright et al. 1987). In infants and toddlers, the carriage of N.
lactamica, a related non-pathogenic organism, predominates (Gold et al. 1978, Cartwright et 
al. 1987, Bakir et al. 2001).  
Meningococcal carriage is a dynamic process, with high rate of turnover and apparently 
multiple carriage periods occurring throughout the life (Ala'Aldeen et al. 2000). The duration 
of carriage is also highly variable (Ala'Aldeen et al. 2000), with the median time of 
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approximately 4 months (Gold et al. 1978). If systemic meningococcal disease occurs, it 
usually manifests within days after the acquisition of a new N. meningitidis strain in 
nasopharynx (Edwards et al. 1977) thought longer carriage period before development of 
invasive disease has also been reported (Ala'Aldeen et al. 2000). Despite the increased risk of 
invasive meningococcal disease after the acquisition of meningococci in the nasopharynx, at 
population level the fluctuations in overall carriage rates have not proven very useful in the 
prediction of outbreaks or emerging epidemics. This reflects the fact that in sharp contrast to 
meningococcal strains isolated from patients that belong to few hyperinvasive lineages only, 
the majority strains isolated from carriers are highly diverse, comprising genotypes rarely or 
never recovered from patients and having thus limited pathogenic potential (Caugant et al.
1988, Jolley et al. 2000, Yazdankhah et al. 2004). During circulation in human populations, 
new lineages of meningococci with increased capacity to cause invasive disease occasionally 
arise from carriage strains thorough genetic recombination and mutation, with capacity to 
spread, sometimes globally (Caugant et al. 1986). 
2.1.4 Adhesion, colonization of human nasopharynx, and invasion 
Humans are the only known reservoir of meningococci. Thus the pathogen is transmitted only 
by aerosol or direct contact with respiratory secretions of patients or healthy human carriers. 
After access to respiratory track, meningococci adhere selectively to microvilli of non-ciliated 
columnar epithelial cells and colonize the nasopharynx (Stephens et al. 1983). The initial 
attachment of meningococci is mediated by long filamentous pili (Stephens and McGee 1981, 
Virji et al. 1992) that specifically recognize complement regulatory protein CD46 (or 
membrane cofactor protein, MCP) on the apical surface of human epithelial cells (Källström
et al. 1997). This interaction between the pathogen and human host is highly specific, as 
evidenced by the inability of piliated strains to bind cells of non-human origin (Virji et al.
1993b). Adhesion of meningococci to host cells leads to down-regulation of pili and capsular 
polysaccharide synthesis (Deghmane et al. 2002). This allows a more intimate contact to host 
cells to be established by colony opacity-associated outer membrane proteins Opa and OpcA 
which both facilitate meningococcal attachment to and invasion of human cultured epithelial 
and endothelial cells but only when present in un-encapsulated background (Virji et al.
1993a). Transient carriage with mild or no symptoms rather than meningitis and/or septicemia 
is the most common outcome of meningococcal infection. The illness results when the 
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organism penetrates the respiratory mucosa and enters the bloodstream of a susceptible host. 
Once entered the blood stream, the bacteria gains access to other parts of body and central 
nervous system by crossing the blood-brain barrier. The mechanisms by which meningococci 
cross the blood-brain barrier composed of tight junction forming epithelial and/or endothelial 
cells are poorly understood but similar to initial contact with nasopharyngeal epithelial cells, 
the interaction between pili and CD46 receptor is likely to be involved (Pron et al. 1997). 
2.1.5 Clinical aspects 
Systemic meningococcal infection is a bacteremic disease often associated with secondary 
infection of skin, meninges and other parts of the body. Though meningococci can cause a 
spectrum of illnesses, two clinically overlapping syndromes, purulent meningitis and 
bloodstream infection (meningococcemia), are by far the most common presentations, septic 
shock with extremely rapid onset being the most devastating form of the disease (Cartwright 
and Ala'Aldeen 1997, Munro 2002). Other manifestations include septic arthritis, pneumonia, 
purulent pericarditis and conjunctivis. Most untreated cases of meningococcal meningitis and 
especially septicemia are fatal. Despite efficient anti-microbial treatment and intensive 
supportive care the case fatality rate from invasive disease has not significantly improved 
during past decades, and the mortality from meningococcal disease has stabilized to about 7-
9% overall, varying from 2-3% in uncomplicated meningitis to 50% or more in septic shock 
(Cartwright and Ala'Aldeen 1997). A nearly equal number of survivors (5%) sustain 
permanent neurological sequelae, mainly deafness (Cartwright and Ala'Aldeen 1997).  
Meningococcal disease is typically of rapid onset and thus treatment should commence as 
soon as the diagnosis is suspected. In most parts of world, meningococci are still highly 
susceptible to penicillin, which is usually the choice of antimicrobial drug for treatment. 
Other drugs such as rifampicin are required to eradicate nasopharyngeal colonization and 
thus, to prevent relapse. As the risk of secondary cases among close contacts such as family 
members is relatively high, chemoprophylaxis combined with vaccination, if available, is 
usually recommended. There are capsular PS or conjugate vaccines against serogroups A, C, 
Y and W135 meningococci, but no vaccine available for serogroup B meningococci.  
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The factors that affect the balance between asymptomatic carriage and bacterial invasion are 
poorly understood. From the bacterial side, the virulence of the colonizing strain and from the 
host side, the state of innate and specific, i.e. adaptive immunity are the most obvious ones 
likely to be involved. Additional factors such as interference by viral infections or 
environmental factors such climatic conditions or smoking that damage integrity of the 
respiratory mucosa, and hence, its effectiveness as a barrier to invasion, may also predispose 
the host to systemic infection (Moore et al. 1990, Fischer et al. 1997, Scholten et al. 1999).  
2.1.6 Genetic factors associated with disease susceptibility 
It has been estimated that host genetic factors contribute to approximately one third of the 
increased risk of disease in siblings of affected cases compared with the risk of disease in 
general population (Haralambous et al. 2003) but the genetic polymorphisms behind this 
finding has not been systemically studied. Variation in host genetic factors may contribute to 
disease at different stages, affecting susceptibility, severity, and/or outcome of infectious 
disease (Emonts et al. 2003). From genetic association studies, defects in sensing, 
recognizing, opsonophagocytic, and lytic pathways, such Toll-like receptor 4 polymorphism 
(Smirnova et al. 2003), hypogammaglobulinemia (Salit 1981), congenital IgM deficiency 
(Hobbs et al. 1967), certain Fc? receptor genotypes (Platonov et al. 1998, van der Pol et al.
2001, Domingo et al. 2002), and especially, defects in classical, alternative, or lectin 
complement pathways (Ross and Densen 1984, Hibberd et al. 1999) are the most obvious 
factors involved in genetically established susceptibility to and/or severity of meningococcal 
infections.  
2.2 Meningococcal surface structures: virulence factors and potential 
vaccine antigens 
Apparently the most important virulence factor of meningococcus is its enormous genomic 
plasticity that allows the pathogen to adapt to different ecological niches and resist varying 
non-specific and specific host defense mechanisms it encounters at different stages of 
infection. Not only the antigenic structure but also the expression of a number of 
meningococcal surface components thought to be of importance for virulence varies through 
processes of transformation, mutation and phase variation (Maiden 1993, Feil et al. 1999, 
Snyder et al. 2001). This variety presents the most important challenge to serogroup B 
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meningococcal vaccine development against which efforts to develop capsular PS-based 
vaccines has been unsuccessful (Wyle et al. 1972).  
2.2.1 Antigenic and phase variability 
Meningococci are transformable, i.e. naturally competent for DNA uptake, enabling a 
mechanism for inter-strain or even inter-species horizontal genetic exchange and antigenic 
variability. This process is the primary mode of DNA change in Neisseria (Feil et al. 1999) 
and has been implicated in the acquisition of sodC from Haemophilus influenzae (Kroll et al.
1998), alteration of penA resulting in penicillin resistance (Spratt et al. 1992), antigenic 
variation of PorA (Feavers et al. 1992a) and Opa proteins (Hobbs et al. 1994), and capsular 
switching (Swartley et al. 1997). Mutations in coding regions provide additional variability 
and are responsible for the micro-heterogeneity of OMPs, such PorA and PorB protein minor 
variants.  
In addition to antigenic variability, many neisserial genes involved in host-parasite 
interactions are subject to phase variation (Tettelin et al. 2000, Snyder et al. 2001), which can 
be defined as high frequency (10-2 to 10-4/cell/generation), reversible on-and-off switching of 
gene expression, contributing to both transmissibility and invasiveness of the organism (de 
Vries et al. 1996). By comparative whole-genome analyses, over 100 putative phase-variable 
genes in the pathogenic Neisseria species has been identified (Snyder et al. 2001). These 
include the genes for pilus (Rytkönen et al. 2004), opacity proteins (Kawula et al. 1988), 
capsular PS (Hammerschmidt et al. 1996b), LOS (Jennings et al. 1999) and HmbR, a 
hemoglobin-binding outer membrane protein (Richardson and Stojiljkovic 1999). The genetic 
basis for this variation depends on the presence of iterative DNA motifs, especially 
homopolymeric tracts, which act as sites of hypermutation. Mutations in tracts situated within 
promoters can alter the degree of gene expression by regulating transcription (e.g. PorA and 
OpcA) while mutations in tracts within coding regions result in on-off switching (e.g. Opa) of 
gene expression at translation level depending on whether the downstream sequences are 
moved in or out of frame for expression. Depending on genes in question, the latter may result 
in on-and-off switching of protein expression or in the case of multiple genes involved in 
LOS biosynthesis, alteration of LOS structure.   
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2.2.2 General characteristics of the cell envelope 
As a typical gram-negative bacterium, the meningococcal cell envelope is composed of three 
layers: an inner phospholipid cytoplasmic membrane, a thin middle peptidoglycan layer, and 
an outer membrane (OM) composed of phospholipids, LOS and numerous proteins embedded 
on it (Fig. 1). In pathogenic strains, isolated from systemic infections, the OM is further 
surrounded by a capsule composed of high-molecular weight anionic polysaccharide. Most 
research has been focused on the capsule and OM components since these are the sites where 
meningococcus interacts with the human host and potential vaccine antigens as well as 
antigenic variability exist.  
Figure 1. Structure of meningococcal cell envelope. Reprinted from Vaccine, Vol 20, Morley SL and Pollard 
AJ. Vaccine prevention of meningococcal disease, coming soon? Pages 666-687, Copyright (2001), with 
permission from Elsevier. 
2.2.3 Polysaccharide capsule 
Capsule is the major virulence factor of meningococcus. With the exception of serogroup A 
meningococci, all the disease associated serogroups B, C, Y and W135 have sialic acid (N-
acetyl neuraminic acid) in their capsular polysaccharides. This confers the organism 
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resistance to host alternative complement pathway mediated attack through mechanisms that 
are not fully understood (Jarvis and Vedros 1987, Ram et al. 1999), partly due to the presence 
of another potentially sialylated molecule, i.e. LOS, on bacterial surface. In vitro, sialic acids 
of both capsule and LOS are prerequisite for bacterial survival in normal human serum (Vogel
et al. 1997, Kahler et al. 1998) and confer resistance to phagocytosis (Estabrook et al. 1992). 
Likewise, in an animal model of meningococcal infection, expression of both sialic acids has 
been reported to be indispensable for bacterial survival (Vogel et al. 1996).  
Like many other virulence factors, the expression of capsular PS is phase variable 
(Hammerschmidt et al. 1996a, Hammerschmidt et al. 1996b), allowing the bacteria to vary 
from adherent, serum sensitive, un-encapsulated phenotype to less-adherent, serum resistant 
encapsulated phenotype. Colonization is favored by the absence of the capsule, un-
encapsulated mutants adhering to human buccal epithelial cells or nasopharyngeal organ 
cultures in greater numbers than the encapsulated parent (Stephens et al. 1993). This is in 
strict contrast to systematic spread: encapsulation is a prerequisite for bacterial survival in the 
blood. In contrast to case isolates that are frequently encapsulated, approximately 40-50% of 
the strains isolated from carriers lack capsule and hence are not serologically groupable 
(Caugant et al. 1988, Ala'Aldeen et al. 2000, Yazdankhah et al. 2004).  
In serogroup B and C meningococci, the capsular PSs are a homopolymers of N-acetyl-
neuraminic acid. The major difference between these two PS lies in the linkage between the 
sialic acid residues, which is ?2-8 in serogroup B and ?2-9 in serogroup C meningococci. The 
serogroup C PS (C-PS) is also usually O-acetylated (Borrow et al. 2000) whereas the 
serogroup B PS (B-PS) is always de-O-acetylated (Jennings et al. 1977). These differences 
are sufficient to alter the immunological properties of B-PS profoundly. Thus, by contrast to 
C-PS, the purified B-PS is only poorly immunogenic in man (Wyle et al. 1972). This has been 
attributed to immunologic tolerance arising from structural and antigenic similarities between 
B-PS and polysialosyl glycopeptides in fetal and adult neural and extra-neural tissues (Finne
et al. 1983a), and exemplifies another mechanism by which pathogenic bacteria may 
circumvent host immunity, i.e. molecular mimicry.  
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2.2.4 Lipooligosaccharide (LOS) 
LOS is the major constituent of the outer leaflet of the meningococcal OM and responsible for 
the physical integrity and proper functioning of the membrane. It is a glycolipid composed of 
three portions: i) an innermost lipid moiety called lipid A, ii) an inner core oligosaccharide 
structure composed 2-keto-3-deoxy-octulosonic acid and heptoses, the latter sugars being 
variably substituted with iii) short polysaccharide side chains but lacking an O-antigen 
characteristic to enteric gram-negative bacteria. The lipid A portion anchors the LOS into the 
outer leaflet of OM, and is responsible for the toxicity of this molecule due to its ability to up-
regulate a number of inflammation mediators either directly or indirectly, leading ultimately 
to septic shock accompanied by disseminated intra-vascular coagulation and multiple organ 
failure (Brandtzaeg et al. 2001). The inner core OS structure is common to most if not all 
immunotypes, with most of the variability lying in the short polysaccharide side chains 
(Griffiss et al. 1987) and forming the basis of division of meningococci into 12 different 
immunotypes (ITs) (Verheul et al. 1993). ITs L1 thorough L9 are found within group B and C 
meningococci and ITs L8 through L11 within group A meningococci, with ITs L10 and L11 
most often associated with the latter serogroup (Verheul et al. 1993).  
Similarly to many other meningococcal genes, the lgt genes responsible for LOS biosynthesis 
are subject to phase variation, most strains having potential to express several alternative 
terminal LOS structures (Jennings et al. 1999, Berrington et al. 2002). In contrast 
nasopharyngeal isolates that usually express the L8 IT, invasive isolates express lacto-N-
neotetraose (LNnT) containing LOS IT (Jones et al. 1992). This structure, antigenically 
identical to carbohydrate moieties of glycosphingolipids present in many human cells 
(Mandrell et al. 1988), is present on many ITs, including L2, L3, L5, L7, and L9, and can be 
endogenously (Mandrell et al. 1991) or exogenously sialylated (Estabrook et al. 1997). 
Besides its suggested role for virulence through molecular mimicry (Mandrell and Apicella 
1993, Moran et al. 1996), sialylation of LNnT confers the organism resistance to killing 
through all the three complement pathways, irrespective of capsular phenotype (Estabrook et 
al. 1997, Vogel et al. 1997, Jack et al. 1998, Jack et al. 2001).  
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2.2.5 Major outer membrane proteins (OMPs) 
Meningococci express a number of major and minor OMPs, some of which can serve as 
targets for bactericidal, opsonic and/or protective antibodies (Saukkonen et al. 1989) and are 
thus important serogroup B vaccine candidates. On the basis of differences in molecular 
weights, five different classes (1 to 5) of major OMPs, named so because of their abundance 
in OM, are recognized (Tsai et al. 1981).  
Class 1 or porin A (PorA) proteins are porins with slight cation selectivity (Tommassen et 
al. 1990). They are present in the OM as trimers, and function as pores through which small 
hydrophilic solutes can pass in a diffusion-like process (Nikaido 1992). PorA proteins are 
generally present in most meningococcal strains but the expression of this protein varies 
considerably (van der Ende et al. 1995, van der Ende et al. 2000); occasionally, the protein 
may be absent (Newcombe et al. 1998, van der Ende et al. 1999). Recently, an outbreak of 
meningococcal disease caused by PorA-deficient C meningococci has been described (van der 
Ende et al. 2003).  
The porA genes responsible for expression of PorA protein in meningococci of different 
subtypes have been cloned and sequenced (Barlow et al. 1989, McGuinness et al. 1990, 
Maiden et al. 1991). On the basis of nucleotide sequence, a 16-stranded ?-barrel topology 
model has been proposed, with eight hydrophilic loops (L1-L8) exposed to the cell surface 
(van der Ley et al. 1991, Derrick et al. 1999) (Fig. 2). Most of the structural diversity is 
confined to two discrete variable regions (VR1 and VR2) in the predicted surface-exposed 
loops 1 and 4 (Maiden et al. 1991, van der Ley et al. 1991), respectively. The major structural 
differences in these two variable regions independently generate two separate subtype-
specific antigenic determinants and form the basis of the serosubtyping (Frasch et al. 1985, 
Abdillahi and Poolman 1988) and PorA VR typing scheme (Russell et al. 2004). Within these 
schemes, the PorA is assigned by the prefix “P1.”, followed by numbers separated by commas 
that describe the subtype designation. Thus, a meningococcal strain with B:15:P1.7,16 
phenotype has subtype determinants P1.7 and P1.16 in the VR1 and VR2, respectively.  
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Figure 2. Topology model of meningococcal PorA protein. Amphipathic ?-sheets form the outer membrane 
spanning regions, with eight hydrophilic loops exposed to cell surface. Reprinted from Meningococcal Disease, 
Cartwright K ed. Surface structures and secreted products of meningococci, Poolman JT et al. Pages 21-34, 
Copyright (1995), with permission from John Wiley & Sons Ltd. 
PorA is immunogenic in humans following infection (Mandrell and Zollinger 1989, 
Guttormsen et al. 1994, Wedege et al. 1998) or vaccination (Wedege and Froholm 1986, 
Rosenqvist et al. 1995, Tappero et al. 1999) and the antibodies induced exhibit both 
bactericidal (Rosenqvist et al. 1995, Milagres et al. 1998, Tappero et al. 1999) and opsonic 
functions (Lehmann et al. 1999) thought to be of importance for host protection against 
systemic disease. However, due considerable inter-strain antigenic variation, a multivalent 
vaccine is needed to increase vaccine coverage if PorA is to be used as a single vaccine 
antigen. 
Class 2/3 or porin B (PorB) proteins are the most abundant proteins of the OM, where they 
function as anion-selective porins (Tommassen et al. 1990). They are structurally related to 
PorA proteins, with eight surface-exposed hydrophilic loops separated by conserved 
membrane spanning ?-sheets (van der Ley et al. 1991, Derrick et al. 1999). All 
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meningococcal strains stably express either of the two mutually exclusive PorB proteins (Tsai
et al. 1981), PorB2 or PorB3, encoded by alternate alleles present at the porB locus. In 
Europe, majority of current serogroup B disease isolates express PorB3 (EU-IBIS).  
The porB genes responsible for expression of PorB protein in meningococci of different 
serotypes have been cloned and sequenced (Feavers et al. 1992b, Bash et al. 1995, Sacchi et 
al. 1998b). Most of the structural diversity is confined to four discrete variable regions (VR1 
through VR4) in the predicted surface-exposed loops 1, 5, 6, and 7, respectively (Feavers et 
al. 1992b, Bash et al. 1995), of the proposed porin structure, and forms the basis of division 
of meningococci into different serotypes (Frasch et al. 1985) and PorB VR types (Sacchi et 
al. 1998b).  
PorB protein is highly immunogenic in humans following infection and vaccination 
(Guttormsen et al. 1993, Delvig et al. 1997, Wedege et al. 2000) but the protective activity of 
these antibodies may be limited due to poor accessibility of especially PorB3 epitopes on 
intact, live bacteria (Michaelsen et al. 2001). Indeed, by contrast to allelic PorB2 and the 
PorA protein (Brodeur et al. 1985, Saukkonen et al. 1987, Saukkonen et al. 1989), 
monoclonal antibodies to PorB3 are less frequently bactericidal and failed to confer protection 
in vivo in an infant rat model of meningococcal infection (Saukkonen et al. 1987, Saukkonen
et al. 1989).  
Class 4 or reduction modifiable protein (Rmp) differs from other major OMPs in terms that 
it is both constitutively expressed as well as antigenically invariable (Lytton and Blake 1986). 
It is a structural, periplasmic protein involved in the maintenance of cell envelope integrity by 
stabilizing the oligomeric forms of a number of OMPs (Jansen et al. 2000, Prinz and 
Tommassen 2000) and linking outer membrane to peptidoglycan layer (Grizot and Buchanan 
2004). As might be predicted from its periplasmic location, antibodies to Rmp are neither 
bactericidal nor opsonic (Rosenqvist et al. 1999), making it less attractive candidate for 
meningococcal vaccines.  
Class 5 or colonial opacity-associated Opa and OpcA proteins are a group of heat-
modifiable proteins that are functionally related but genetically and structurally distinct. Both 
proteins mediate meningococcal adhesion to and invasion of epithelial and endothelial cells, 
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Opa proteins mainly by binding to members of the carcinoembryonic antigen-related cell 
adhesion molecule (CEACAM) family (Virji et al. 1996) while OpcA protein interacting 
indirectly via vitronectin with ?-integrins on endothelial cells (Virji et al. 1994) and directly 
with heparan sulphate proteoglycans on epithelial cells (de Vries et al. 1998).  
Opa proteins are encoded by a family of three to four genes that undergo high-frequency on-
off phase (Stern and Meyer 1987, Kawula et al. 1988, Woods and Cannon 1990) and 
antigenic variation of expression (Hobbs et al. 1994, Malorny et al. 1998), a single strain of 
N. meningitidis being able to express from none up to several distinct Opa proteins due to 
genetic rearrangements within the pentameric repeat units in coding region of the amino-
terminal leader peptide (Stern and Meyer 1987). On the basis of nucleotide sequence, a two-
dimensional eight-stranded ?-sheet topology model has been proposed, with four hydrophilic 
loops (L1-L4) exposed to the cell surface (Malorny et al. 1998). Loops 2 and 3 are highly 
variable in sequence (Malorny et al. 1998) and involved in the interaction with CEACAM 
receptors on host epithelial cells (Virji et al. 1996, de Jonge et al. 2003).  
OpcA protein (formerly know as 5C or Opc) differs from Opa proteins in terms of that only 
one functional gene (opcA) is present in meningococcal genome (Zhu et al. 1999); in some 
epidemic clones it may be absent (Seiler et al. 1996). By contrast to highly variable opa 
genes, opcA shows only limited sequence variability (Seiler et al. 1996). Nevertheless, due to 
variation in the length of a polycytidine strecth in the promoter region, the expression of 
OpcA is hypervariable at transcriptional level, leading to bacteria with different OpcA levels 
on their OM (Sarkari et al. 1994). On the basis of nucleotide sequence, a two-dimensional 
eight-stranded ?-sheet topology model has been proposed, with 10 transmembrane strands and 
five hydrophilic loops (L1-L5) exposed to the cell surface (Merker et al. 1997). In the crystal 
structure, the loops protrude from the ?-barrel and form a positively charged crevice that have 
been suggested to be the binding site to negatively charged host proteoglycan polysaccharide 
(Prince et al. 2002).   
Although the Opa and especially the OpcA protein have been shown to be highly 
immunogenic and able to induce bactericidal antibodies in humans following infection or 
vaccination (Rosenqvist et al. 1993, Danelli et al. 1996, Milagres et al. 1998), the high degree 
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of phase and/or antigenic variability has been considered the major impediment to vaccine 
application. 
The minor OMPs are discussed later in the “Other serogroup B vaccine candidates” section.  
2.2.6 Other surface structures 
Pili are long filamentous multimeric proteins protruding from the OM to bacterial surface. In 
encapsulated strains, pili are essential for adhesion of meningococci to human epithelial and 
endothelial cells (Stephens and McGee 1981, Virji et al. 1991). Similarly to a number of other 
meningococcal surface structures, also pili undergo extensive antigenic and phase variation 
(Tinsley and Heckels 1986, Nassif et al. 1993, Rytkönen et al. 2004), and hence, are 
considered less attractive vaccine candidates.   
2.3 Immunity and host defense mechanisms 
A variety of host defense mechanisms are involved in protection against meningococcal 
disease. Similarly to other pathogens colonizing the upper respiratory tract, at mucosal sites, 
non-specific and specific factors inhibiting the attachment, colonization and penetration of 
bacteria through the respiratory epithelium provide the first line defense. If penetration of 
bacteria through the respiratory epithelium and entrance to bloodstream occurs, humoral and 
cellular components of blood and associated tissues provide the last phase of host defense to 
prevent excessive intra-vascular bacterial multiplication and the development of 
overwhelming disease. With this respect, specific antibody (IgG or IgM) and the complement 
system play the most critical role (Goldschneider et al. 1969a). Acquired or genetic absence 
of either of these serum factors predisposes individual to at risk for systemic meningococcal 
infection (Hobbs et al. 1967, Salit 1981, Figueroa et al. 1993). 
2.3.1 Development of immunity 
Natural antibodies against meningococci develop with age and are associated with an increase 
in serum bactericidal activity (SBA) (Goldschneider et al. 1969a, Goldschneider et al. 1969b). 
Infants are thought to be protected from disease through the acquisition of maternally derived 
antibody during gestation and lactation. With the weaning immunity, the incidence of 
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meningococcal disease peaks at 6 months to 2 years of age, followed by progressive decrease 
up to 12 years of age when the attack rate has declined to adult level and natural immunity 
developed (Goldschneider et al. 1969a). Although poorly understood, this natural 
immunization is thought to occur through prolonged or intermittent colonization at the 
mucosal surface by non-pathogenic meningococci or commensal Neisseria such as N. 
lactamica (Goldschneider et al. 1969b, Gold et al. 1978, Robinson et al. 2002, Troncoso et al.
2002). Both capsular and sub-capsular antigens seem to participate in generation of systemic 
immune response (Goldschneider et al. 1969b, Jones and Eldridge 1979, Wedege et al. 2003, 
Jordens et al. 2004) thought to be of major importance for host immunity against invasive 
disease. While beneficial for systemic immunity, the carriage does not, however, always seem 
to prevent re-colonization with either the homologous or heterologous meningococcal strains 
(Ala'Aldeen et al. 2000).  
The contribution of carriage of non-related species to development of immunity is less clear. 
Nevertheless, serological cross-reactions, also between meningococci and species of other 
genera (Robbins et al. 1972, Kasper et al. 1973, Glode et al. 1977, Bøvre et al. 1983, Devi et 
al. 1991), are quite common  and thus likely to be an important mechanism by which majority 
of humans develop natural immunity against meningococci.  
The importance of mucosal immunity to protection against meningococcal disease has been 
less studied but as the portal of entry is likely to play an important role on host protection. 
After meningococcal carriage, an increase in specific salivary IgA concentration has been 
detected (Robinson et al. 2002). Whether this carriage-induced mucosal immunity protects 
against invasive meningococcal disease remains to be determined. 
2.3.2 Complement
The complement system appears to have a unique role in the protection of host from 
meningococcal infection, as highlighted by the high frequency of complement deficiencies in 
patients with systemic meningococcal disease (Ross and Densen 1984, Figueroa et al. 1993) 
and a number of mechanisms that pathogenic Neisseria has evolved to combat this powerful 
defense mechanism (Ram et al. 1999, Jarva et al. 2005). It is a part of the innate immune 
system consisting of over 30 soluble or membrane bound proteins, and acts in defense against 
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infection directly by its inflammatory, opsonic and lytic activities, and indirectly by 
enhancing antibody responses against invading pathogens (reviewed in (Erdei et al. 1991, 
Frank and Fries 1991, Kinoshita 1991)). Three pathways of complement cascade activation 
have been described: the classical pathway, the alternative pathway, and the lectin pathway 
(Fig. 3). Although initiated by different recognition mechanisms, all these pathways converge 
at C3 level, leading to deposition of opsonically active C3b and iC3b fragments on bacterial 
surface and, through the continuation of complement activation through the common terminal 
pathway (C5-9) and deposition of membrane attack complex (MAC) to outer membranes of 
gram-negative bacteria, target cell lysis. 
Figure 3. Three pathways of complement cascade activation. Reprinted from Microbes and Infection, Vol 1, 
Mold C.  Role of complement in host defense against bacterial infection. Pages 633-638, Copyright (1999), with 
permission from Elsevier. 
Acquired or genetic deficiency in any of these complement pathways predisposes individual 
to at increased risk for systemic meningococcal infection, with the preponderance of 
meningococcal infections among individuals with C3 (C3, factors H and I), alternative 
pathway (properdin, factor D), and especially, late complement component deficiencies 
(LCCD; C5 to C9) (Ross and Densen 1984). With the exception of C5 deficiency, 
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deficiencies in any other components (C6 through C9) of the terminal pathway predispose 
individual to meningococcal infections solely due to inability to assemble the MAC into 
bacterial membrane and hence, to express complement mediated serum bactericidal activity.  
2.3.3 Serum bactericidal activity (SBA) 
Due to inverse relationship between the age-related decrease in the incidence of 
meningococcal disease with the acquisition of SBA (Goldschneider et al. 1969a) and the 
preponderance of neisserial infections among patients with LCCD (Figueroa et al. 1993), 
SBA has been considered as the functional requirement of utmost importance for protection 
against meningococcal disease. Sialic acid containing encapsulated meningococci, in contrast 
to their un-sialylated, un-encapsulated counterparts, activate complement poorly and are 
therefore relatively resistant to bactericidal activity of normal human serum (Vogel et al.
1997, Kahler et al. 1998). Thus, specific antibodies and hence, the recruitment of the classical 
pathway is necessary for lysis of encapsulated organisms. IgG antibodies to serogroup A and 
C capsular PS (Goldschneider et al. 1969b, Williams et al. 2003) as well as certain OMPs, 
especially the PorA and OpcA proteins, seems especially efficient with this functional respect 
(Saukkonen et al. 1987, Rosenqvist et al. 1993) and mouse antibodies against these proteins 
has been further shown to be highly protective in vivo in experimental animal models of 
meningococcal infection ((Saukkonen et al. 1987, Saukkonen et al. 1989, Toropainen et al.
2001) and our unpublished observations). The mechanisms by which specific antibody 
augments bacterial lysis are not fully understood but for PorA antibody this seems to be due 
to re-targeting of MAC from non-lytic to lytic loci rather than an increase in the total amount 
of MAC formed (Drogari-Apiranthitou et al. 2002). 
2.3.4 Opsonophagocytic activity (OPA) 
Besides SBA, several reports suggest that also OPA is an important defense mechanism 
against meningococcal infections, especially those caused by serogroup B organisms (Ross et 
al. 1987, Schlesinger et al. 1994, Platonov et al. 1998). While SBA is dependent on the 
deposition MAC to bacterial membranes through activation of the whole complement 
cascade, IgG-mediated phagocytosis is not. IgG-mediated phagocytosis is however amplified 
by complement activation but only requires deposition of opsonically active C3 split products 
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(C3b, iC3b, C3dg) on the bacterial surface. IgG and deposited C3 fragments can therefore 
function in concert as opsonins, targeting the invading pathogen for ingestion and killing by 
professional phagocytes through binding to Fc (FcR) and complement (CR) receptors. 
Increased OPA by polymorphonuclear leukocytes (PMNLs) has been shown in human sera 
taken at convalescence and after vaccination with serogroup B outer membrane vesicle 
(OMV) vaccine (Roberts 1970, Halstensen et al. 1984, Sjursen et al. 1987, Halstensen et al.
1989, Lehmann et al. 1999). As for SBA, antibody to both capsular as well as sub-capsular 
antigens (Roberts 1970, Halstensen et al. 1984, Lehmann et al. 1999) seems important with 
this functional respect. The relative contribution of antibody induced complement-mediated 
bacterial lysis and phagocytosis to host immunity against meningococcal infections remains 
open.
2.3.5 Effect of antibody specificity on functional activity 
To opsonize or initiate complement-mediated bacterial lysis, the first step is the binding of 
antibody to bacterial surface. As the main and outermost surface component, the capsular PS 
is the main target for protective antibodies against encapsulated bacteria, including 
meningococcus.  
For serogroup A and C meningococci, the importance antibodies to capsular PS as the 
mediators of SBA and OPA has been clearly shown (Goldschneider et al. 1969b, Roberts 
1970, Andreoni et al. 1993, Schlesinger et al. 1994, Williams et al. 2003), and vaccines based 
on either plain PS or PS conjugated to a protein carrier are highly effective against disease 
caused by these serogroups (Artenstein et al. 1970, Wahdan et al. 1973, Peltola et al. 1977, 
Ramsay et al. 2001). This does not hold true for serogroup B meningococci against which 
SBA and OPA has been attributed to be primarily against non-capsular antigens (Zollinger 
and Mandrell 1983, Williams et al. 2003), and the purified capsular PS of which is poorly 
immunogenic (Wyle et al. 1972). Nevertheless, antibodies to B-PS, predominately the IgM 
isotype, are naturally present in the majority of the adult population (Leinonen and Frasch 
1982, Granoff et al. 1995). Specific immune responses to B-PS have been observed in the 
majority of adults and in 30% of children recovering from serogroup B meningococcal 
disease (Griffiss et al. 1984, Granoff et al. 1995, Andersen et al. 1997). Due to the relatively 
low avidity (Mandrell and Zollinger 1982) and the poor bactericidal activity of anti-B-PS 
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antibodies, especially in the presence of human complement (Zollinger and Mandrell 1983), 
their contribution to protective immunity against serogroup B meningococci has been 
challenged. 
2.3.6 Effect of antibody class and subclass on functional activity 
Not all antibody classes and subclasses are equally effective in mediating bacterial lysis or 
phagocytosis. Of the five immunoglobulin-classes in humans (IgG, IgM, IgD, IgA, IgE), IgG 
and IgM constitute the bulk of serum antibodies and play the most important role in 
protection against systemic meningococcal disease.   
IgM antibodies constitute the major component of natural antibodies and are the first class of 
antibodies produced in a primary response to antigen. Due to their pentavalent structure, they 
are extremely potent activators of complement and hence mediate both efficient SBA and/or 
OPA by binding to complement receptors on fixed and peripheral phagocytes and possibly 
also by binding to more recently discovered IgM receptors (Fc?/?R) on macrophages 
(Shibuya et al. 2000).
Of the four human IgG subclasses (IgG1-4) in humans, IgG1 and IgG3 are the predominant 
subclasses produced against protein antigens such as serogroup B OMV vaccines (Wedege 
and Michaelsen 1987, Sjursen et al. 1990, Naess et al. 1999). They are potent complement 
activators and interact with all known three human Fc?RI-III receptors, thereby mediating 
both efficient SBA and phagocytosis. IgG2, the main subclass produced by B-cells upon 
polysaccharide vaccination and capable of binding effectively to Fc?RII receptor only, has 
been reported to be effective at high epitope density only while IgG4 is relatively ineffective 
with both functional respects (Aase and Michaelsen 1994).  
To study the effect of antibody isotype on SBA and OPA, a panel of mouse-human chimeric 
Mabs of all the four human IgG subclasses with identical variable (V) genes against the P1.16 
epitope on PorA protein has recently been generated and characterized for their effector 
functions in vitro (Vidarsson et al. 2001). While the IgG1-3 subclasses mediated efficient 
bacterial lysis (relative activity IgG1 = IgG3 > IgG2) and phagocytosis (relative activity IgG3 
> IgG1 >> IgG2), IgG4 was unable to do so. How these differences in functional activities in
vitro are reflected to protection in vivo is not known. 
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2.4 Meningococcal vaccines 
Since the recognition of the importance of humoral immunity for protection against 
meningococcal disease, attempts to prevent this devastating disease through vaccination has 
been practiced for nearly 100 years.  
2.4.1 Early vaccines 
With the encouraging results obtained by whole-cell vaccines against typhoid fever, the first 
efforts to develop vaccines against meningococcal disease using similar approach began as 
early 1910s (reviewed in (Frasch 1995)). The field trials with these early vaccines based on 
whole, heat-killed bacteria yielded mixed but generally poor results. Further, side effects, 
probably caused by high amount of endotoxin (LOS), were common and often severe. Thus, 
serum therapy (reviewed in (Casadevall and Scharff 1994)) remained as the only choice for 
treatment to late 1930s until the newly discovered antibiotics sulfonamide and, later on, 
penicillin replaced it.  
2.4.2 Capsular polysaccharide (PS) vaccines 
During the Second World War, several outbreaks caused by serogroup A and C meningococci 
among army recruits prompted early attempts to produce vaccines from purified capsular PS 
(reviewed in (Frasch 1995)). Three major breakthroughs had accounted the interest in 
capsular PS as the vaccine candidate. The first was the demonstration (Rake 1933), and later 
on, the purification and chemical characterization (Scherp and Rake 1935), of the capsular PS 
from freshly isolated meningococcal isolates. The second was the description of the first 
reliable and reducible animal model of meningococcal infection model (Miller 1933) that 
allowed the protective activity of experimentally raised meningococcal anti-sera to be reliably 
evaluated (Miller and Castles 1936). Finally, using this model, Scherp and Rake demonstrated 
that the protection afforded by anti-serogroup A meningococcal horse serum was directly 
proportional to the amount of anti-capsular PS antibody it contained (Scherp and Rake 1945). 
With the encouragement of these studies and the contemporary success in the development of 
pneumococcal PS vaccines (MacLeod et al. 1945), the first human studies with 
meningococcal vaccines based on purified capsular PS were conducted in 1940s (Kabat et al.
1945). However, the results were not satisfactory, and with the beginning of antibiotic era, the 
40
interest in meningococcal research and vaccine development waned until the first sulfonamide 
resistant strains emerged in early 1960s. 
With the first outbreaks caused by sulfonamide resistant strains among the U.S. army recruits 
during the Vietnam War (Millar et al. 1963), the development of first consistently 
immunogenic meningococcal vaccines based on capsular PS started at the Walter Reed Army 
Institute of Research at late 1960s. A major breakthrough in meningococcal vaccines 
development took place when Goldschneider et al. (Goldschneider et al. 1969a, 
Goldschneider et al. 1969b) in a series of seminal studies indicated the importance 
bactericidal anti-capsular antibody for protection and developed a method for the purification 
of capsular PS in a high molecular weight form (Gotschlich et al. 1969); to be consistently 
immunogenic in man, PS must have molecular weights > 100 000. The first clinical trials with 
the new, high molecular weight serogroup C capsular PS vaccine conducted in late 1960s to 
early 1970s among military recruits showed an excellent efficacy (about 90%) which, as 
expected, was limited serogroup C meningococci (Artenstein et al. 1970, Gold and Artenstein 
1971). Later on, using same purification method for serogroup A meningococci, successful 
efficacy trials with serogroup A PS vaccine were conducted in epidemic situations in Finland 
(Peltola et al. 1977) and Africa (Wahdan et al. 1973), leading to international licensing of 
serogroup A and C capsular PS based vaccines.  
Currently, there are two types of PS vaccines, the bivalent serogroup A/C and the tetravalent 
A/C/Y/W135, in routine clinical use for controlling outbreaks and epidemics caused by 
serogroups covered by them. A drawback of PS vaccines limiting their utility in routine 
childhood immunization programs has been their limited efficacy (of especially serogroup C) 
and the short duration of protection among infants and young children, primarily arising from 
the T-cell independent nature of the immune response that PS antigens induce. A T-cell 
dependent immune response, and hence, induction of immunological memory, can be 
achieved through conjugation of PS antigen to a protein carrier. Thus, new generation glyco-
conjugate vaccines have and are currently being developed using the same, successful 
principal as was used to develop effective childhood vaccines against meningitis caused by 
Haemophilus influenzae type B (reviewed in (Mäkelä and Käyhty 2002)) and which led to 
nearly complete disappearance of this disease in countries that incorporated it to infant 
vaccination schedule. In 1999, UK became the first country that introduced meningococcal 
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group C vaccine into national childhood immunization program, followed by several 
European countries including Ireland, Iceland, Luxemburg, the Netherlands and Spain (EU-
IBIS 2002). More recently, a new quadrivalent serogroup A/C/Y/W135 polysaccharide 
diphtheria toxoid conjugate vaccine was licensed in the U.S. (Mitka 2005).  
No PS based vaccine exists to prevent disease caused by serogroup B meningococci. By 
contrast to serogroup A and C PS, the purified B-PS is only poorly immunogenic (Wyle et al.
1972), even when conjugated to carrier proteins such as tetanus toxoid (Jennings and 
Lugowski 1981). As stated earlier, this has been attributed to antigenic similarity of the B-PS 
to sialic acid moieties in human tissues (Finne et al. 1983b). To overcome the poor 
immunogenicity and the concerns of safety raised over B-PS based vaccines (Finne et al.
1983b), Jennings et al. substituted the N-acetyl groups of the sialic acid residues with N-
propionyl groups prior to its conjugation to a carrier protein (Jennings et al. 1986). While 
promising experimental animals (Jennings et al. 1986, Ashton et al. 1989, Granoff et al.
1998), including non-human primates (Fusco et al. 1997), such vaccines have failed to induce 
a functional antibody responses in man (Bruge et al. 2004). Further, even when using N-
propionyl conjugates, a subset of antibodies show auto-reactivity with host polysialic acid 
(Granoff et al. 1998). Considerable attention has therefore been given to non-capsular 
antigens, mainly OMPs either in the form of outer membrane vesicles (OMVs) (Fredriksen et 
al. 1991, Sierra et al. 1991, Peeters et al. 1996) or complexes (Boslego et al. 1995) or more 
recently, purified recombinant proteins (Muttilainen et al. 1995, Martin et al. 1997, West et 
al. 2001), as alternative strategies for serogroup B vaccine development.  
2.4.3 Serogroup B outer membrane vesicle (OMV) vaccines 
Attempts to develop vaccines against serogroup B disease have been ongoing since the late 
1970’s; none has yet been fully successful (reviewed by (Frasch 1995)). While the protective 
efficacy of single component vaccines, such as diphtheria toxoid, tetanus toxoid, 
pneumococcal and meningococcal serogroup A and C capsular PS, has often been very good, 
for serogroup B vaccine development this approach was not rational due to lack of knowledge 
on the specificity of potentially protective sub-capsular antigens. Thus, vaccines based on 
multiple rather than single bacterial component were considered the most relevant choice.  
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The first attempts to develop vaccines against serogroup B disease were based on relatively 
crude OMP preparations from which majority of the LOS responsible for side effects was 
removed by extraction of bacterial cells with appropriate detergents (Frasch and Robbins 
1978). The OMPs were then separated from detergents with ethanol precipitation and 
subsequently re-suspended in sodium chloride. While promising in animal studies (Frasch and 
Robbins 1978, Craven and Frasch 1979), the vaccines failed to induce protective immune 
response in man (Frasch et al. 1982); this was later on attributed to the loss of protein tertiary 
structure due to precipitate nature of the preparations (Frasch and Peppler 1982).  
The next step was then to try producing a soluble vaccine in which the proteins would be 
displayed in more native conformation, and hence, capable of inducing protective immune 
response. When grown in liquid culture, meningococci release into medium so called blebs, 
i.e. outer membrane vesicles (OMVs) complete with outer membrane proteins, LOS and 
lipids in their native form (DeVoe and Gilchrist 1973). The OMVs are relatively simple to 
purify from liquid cultures or to produce artificially by extracting bacterial cells with suitable 
detergents. With the subsequent, selective depletion of LOS by appropriate detergent 
treatment, soluble OMV vaccines with satisfactory safety profile and immunogenicity can be 
relatively easily gained (Frasch and Peppler 1982, Frasch et al. 1982); adsorption to 
aluminum salts (Frasch et al. 1988) or non-covalent complexing to capsular PS (Peppler and 
Frasch 1982) was further shown to increase OMV vaccine immunogenicity. Since then, a 
number of efficacy trials with serogroup B OMP vaccines, composed mainly of class 1 
(PorA), class 2/3 (PorB), and class 5 major OMPs, have been conducted in response to 
prolonged serogroup B epidemics, with variable results (Table 1).  
2.4.4 Efficacy trials of serogroup B OMP and OMV vaccines 
The first efficacy trial with a serogroup B OMP vaccine was conducted in 1981 in Cape 
Town, South Africa where 4 440 children aged from 4 months to 5 years were enrolled 
(Frasch et al. 1983). The vaccine was based on OMPs prepared from an un-encapsulated 
mutant of the group B serotype 2a strain M986 complexed to an equal amount of purified 
high molecular weight group B capsular PS and contained no adjuvant. While immunogenic 
in all age groups, the number of study participants was too small to draw definite conclusion 
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about vaccine efficacy (2 cases in OMP vaccine versus 4 cases in serogroup A/C vaccine 
group) (Frasch et al. 1983).  
The second vaccine efficacy trial was conducted in Cuba in 1987-1989 (Sierra et al. 1991). 
The study vaccine (VA-MENGOC-BC™), prepared at the Finlay Institute, Havana, Cuba, 
was composed of LOS depleted OMVs extracted from a clinical disease isolate (Cu385, 
B:4:P1.19,15) representative of the local epidemic that was subsequently enriched with un-
characterized “high molecular weight protein complexes” (Sierra et al. 1991). This 
preparation was subsequently conjugated non-covalently in 1:1 proportion to serogroup C 
capsular PS, and finally absorbed to aluminum hydroxide. In this double-blind, placebo 
controlled, cluster randomized efficacy study, about 106 000 10-14 years old students from 
197 boarding schools were enrolled. During 16 months of follow-up, 4 cases occurred among 
the vaccine recipients compared to 21 cases among those given placebo, and a good efficacy 
of 83% (95% CI 42-95) against serogroup B disease was detected (Sierra et al. 1991). In an 
attempt to control a prolonged serogroup B epidemic in Brazil caused by a variety of 
serogroup B strains including the B:4:P1.15 phenotype, two large separate case-control 
studies with Cuban vaccine were subsequently conducted in Sao Paolo (de Moraes et al.
1992) and Rio de Janeiro (Noronha et al. 1995). With a total of 4 million children aged 3 
months to 9 years enrolled, an efficacy of about 70% was detected for children 4 years or 
older but was much lower for younger children and absent in infants (de Moraes et al. 1992, 
Noronha et al. 1995). There was also a trend to better protection during the first than the 
second half-year observation period, suggesting that protection could be of short duration 
(Noronha et al. 1995).  
The next efficacy trial was conducted in Iquique, Chile, from 1987 to 1989 (Boslego et al.
1995). The vaccine, developed at the Walter Reed Army Institute of Research (WRAIR), 
Washington, DC, differed from the Cuban and Norwegian (see below) OMV vaccines in 
several respects (Boslego et al. 1995). First, in the extraction of OMPs from a clinical disease 
isolate (8257, B:15:P1.3) representative of the Iquique outbreak, a zwitterionic detergent 
Embigen BB rather than deoxycholate was used.  Second, the OMPs were not in the form of 
vesicles but consisted primarily of multimeric membrane subunits that were essentially free of 
LOS. Finally, the vaccine contained no class 5 or other low molecular weight OMPs. 
Similarly to the Cuban vaccine, the OMPs were conjugated non-covalently to serogroup C 
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capsular PS, and finally absorbed to aluminum hydroxide.  In this double-blind, placebo 
controlled, randomized efficacy trial, approximately 40 000 volunteers of ages of 1-21 years 
were enrolled (Boslego et al. 1995). After 20 months of follow-up a good efficacy of 70% 
(95% CI 3-93) was detected for older children (?5 years); in younger children (1-4 years) no 
protection was observed (Boslego et al. 1995). 
In a double-blind, placebo controlled, cluster randomized efficacy study conducted in Norway 
in 1988-1991, around 172,000 secondary school students aged 14-16 years were enrolled 
(Bjune et al. 1991a, Bjune et al. 1991b). The study vaccine (MenBvac™), developed at the 
Norwegian Institute of Public Health (NIPH), Oslo, Norway, was composed of LOS depleted 
OMVs extracted from a clinical disease isolate (44/76, B:15:P1.7,16) representative of the 
local epidemic, absorbed aluminum hydroxide (Fredriksen et al. 1991). In contrast to the 
Cuban and WRAIR vaccines it contained no meningococcal capsular PS. After a relatively 
long follow-up period of 29 months, an efficacy of 57% (lower confidence limit 28%) was 
observed (Bjune et al. 1991a, Bjune et al. 1991b). Similar to the efficacy trial with the Cuban 
vaccine in Rio de Janeiro (Noronha et al. 1995), there was evidence of better protection 
during the first than the second half observation period (Holst et al. 2003). In retrospective 
calculations, an efficacy of 87% was calculated for the first 10-month observation period 
whereas it was as low as 30% for the last 10 months (Holst et al. 2003).  
Currently, a “tailor made” OMV vaccine (MeNZB™) (Holst et al. 2005, Oster et al. 2005) is 
undergoing a clinical trial in New Zealand (Ameratunga et al. 2005) to combat to a prolonged 
and intense group B meningococcal disease epidemic (Baker et al. 2001). The vaccine was 
produced in collaboration of NIPH with Chiron (Sienna, Italy) from a local epidemic strain 
B:4:P1.7b,4 (Martin et al. 1998). 
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While not satisfactory with all respects, the main importance of these efficacy trials conducted 
with two-dose schedules was the demonstration that vaccines based on non-capsular antigens 
do provide significant protection against serogroup B disease (50% to 80%), encouraging 
further vaccine development in this field to improve their immunogenicity and the persistence 
of protection especially amongst the youngest children who are most vulnerable to serogroup 
B disease. As the protection seemed relatively short-lived (Noronha et al. 1995, Holst et al.
2003), it has been suggested that a third dose given 6-8 months after the primary 
immunization series could be beneficial (Frasch 1995).   
2.4.5 Immunogenicity trials of serogroup B OMV vaccines  
One important issue hampering the development of serogroup B meningococcal vaccines has 
been the lack of reliable laboratory correlates or surrogates for protective immunity, 
necessitating the use of long-lasting, laborious, and expensive efficacy trials. Although the 
antibody responses in connection with these efficacy trials have been analyzed extensively 
(Høiby et al. 1991, Rosenqvist et al. 1991, Sierra et al. 1991, Holst et al. 2003, Wedege et al.
2003), there is still much uncertainty about the specificity and functional mechanisms of 
antibodies providing protection against serogroup B disease. In particular, despite the good 
predictive value of SBA for the protective efficacy of serogroup A and C capsular PS based 
vaccines the importance of SBA for protection against serogroup B disease remains partly 
open. Thus, additional immunogenicity trials with the Norwegian and the Cuban OMV 
vaccines have been conducted later in Iceland (Perkins et al. 1998) and Chile (Tappero et al.
1999), assessing immune responses in different age groups (infants, toddlers, and adults in 
Chile and teenagers in Iceland).  
In the randomized, double-blind, placebo-controlled trial with the Norwegian and the Cuban 
OMV vaccines carried out among Icelandic teenagers in 1992-93, the main focus was at the 
evaluation of SBA and antibody concentrations measured by enzyme immunoassay (EIA) as 
potential correlates for vaccine efficacy (Perkins et al. 1998). As described above, both 
vaccines had been previously shown to be efficacious for older children and adults in large 
separate efficacy trials (Bjune et al. 1991b, Sierra et al. 1991). In contrast to results from 
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these efficacy trials, the proportion of SBA and EIA responders, defined as individuals with a 
4-fold rise in bactericidal antibody titer or anti-OMV IgG antibody level compared with pre-
vaccination level, was found to be generally lower among the Cuban vaccine recipients than 
the Norwegian vaccine recipients (Perkins et al. 1998). Six weeks after the second dose, 25% 
and 54% of the Cuban vaccine recipients, and 71% and 74% of the Norwegian vaccine 
recipients showed a response in SBA and EIA, respectively, against their homologous vaccine 
strains. Based on these results it was concluded that SBA and EIA activities might not be 
optimal correlates for serogroup B OMV vaccine efficacy (Perkins et al. 1998).  
Another issue related to vaccines based on OMPs from a single meningococcal strain that 
remains to be settled is the specificity of antibodies and hence, the extent of protection they 
induce. In the Brazilian and Norwegian efficacy trials, no evidence for serosubtype- or strain-
restricted protection for the Cuban and the Norwegian OMV vaccines was detected (de 
Moraes et al. 1992, Wedege et al. 1999), suggesting that both vaccines can provide some 
protection against heterologous strains as well. In line with these results, in the Chilean and 
Icelandic immunogenicity trials, adults, teenagers and children aged 2 to 4 years were able to 
develop SBA response against both the homologous, i.e. vaccine type, and heterologous 
strains (Perkins et al. 1998, Tappero et al. 1999) though against heterologous strains much 
lower responses were detected. This was in contrast to infants younger than 1 year among 
whom SBA responses were mainly directed to homologous PorA protein and no post-
vaccination SBA response against the heterologous strains was detected (Tappero et al. 1999).
To overcome possible limitations of OMV vaccines arising from the variability of PorA 
protein, yet exploiting its good immunogenicity and ability to induce bactericidal antibody 
responses, a hexavalent PorA vaccine (HexaMen) has more recently been developed at the 
Netherlands Vaccine Institute, NVI (formerly National Institute of Public Health and the 
Environment, RIVM), in the Netherlands. This vaccine is composed of OMVs from two 
genetically engineered trivalent strains, each expressing three different PorA proteins 
(Claassen et al. 1996), together covering approximately 80% of the prevalent strains in the 
UK  (Cartwright et al. 1999). Clinical phase I and II studies have shown this vaccine to be 
safe and immunogenic in infants, toddlers and school children, and SBA responses against all 
of the six PorA subtypes included in the vaccine have been detected (Cartwright et al. 1999) 
(de Kleijn et al. 2000). However, multiple doses of vaccine were required to induce 
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significant rise in SBA and differences were found in the magnitudes of SBA responses to 
different PorAs, suggesting intrinsic differences in their immunogenicity. To provide even 
broader protection, a nonavalent vaccine, containing the nine most common PorA subtypes in 
the industrialized countries, is currently being developed in collaboration of NVI with Wyeth 
(NJ, USA).
More recently, a new experimental approach to broaden immunity of the conventional OMV 
vaccines has been described. In this approach, sequential immunization with three doses of 
microvesicles (MVs) or OMVs prepared from three antigenically different strains rather than 
one meningococcal strain is used (Moe et al. 2002). The rationale behind this approach is that 
sequential immunization with MVs or OMVs prepared from antigenically different 
meningococcal strains would direct the immune response from immunodominant, serotype or 
serosubtype specific one to more conserved, broadly protective antigens that normally are 
poorly immunogenic when repeated injections are given with OMVs prepared from one 
strain.
2.4.6 Other serogroup B vaccine candidates 
In addition to major OMPs in the form of OMVs, a variety of methods have been developed 
to express a number of major OMPs in heterologous expression systems. After purification 
and refolding in the presence of artificial membranes (liposomes) or appropriate detergent 
micelles, good antibody responses in mice against PorA (Muttilainen et al. 1995, Idänpään-
Heikkilä et al. 1996, Ward et al. 1996, Christodoulides et al. 1998), PorB (Wright et al.
2002), and OpcA (Jolley et al. 2001) proteins with bactericidal and infant rat protective 
activity have been gained, indicating the feasibility of these methods. The main advantage of 
these approaches is that the vaccine antigens are being presented without of irrelevant 
bacterial components, thus directing the immune response to epitopes thought to induce 
protective antibodies also in humans. 
Besides major OMPs, either in the form of OMVs or recombinantly produced, purified and 
refolded antigens, also LOS (Plested et al. 1999, Plested et al. 2003) and a number minor 
OMPs have been considered as vaccine antigens. These include the constitutively expressed 
OMP of unknown function, Neisserial surface protein A (NspA) (Martin et al. 1997, Moe et 
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al. 2001), and a number environmentally regulated proteins thought to be essential for 
bacterial survival through their involvement in iron acquisition pathways, such as transferrin-
binding proteins TbpA and TbpB (Schryvers and Morris 1988, Ala'Aldeen et al. 1994b), a 70 
kDa protein FetA (formerly known as FrpB) (Ala'Aldeen et al. 1994a) and a 37 kDa ferric 
binding protein FbpA (Mietzner et al. 1984).
More recently, as a part of completed meningococcal serogroup B genome sequence project 
(Tettelin et al. 2000), a large number of novel proteins have been discovered (Pizza et al.
2000). Some of these are conserved in sequence, likely to be expressed constitutively, surface 
exposed on encapsulated meningococcal strains, able to elicit bactericidal, opsonic and/or 
animal protective antibody responses in mice, and hence, considered promising as vaccine 
candidates (Comanducci et al. 2002, Masignani et al. 2003, Welsch et al. 2003, Welsch et al.
2004). 
The utilization of the cross-reactivity between N. meningitidis and N. lactamica (Troncoso et 
al. 2002) has also been recently explored (Oliver et al. 2002). Despite the lack of bactericidal 
antibodies, antigens from N. lactamica have been shown protect mice against experimental 
meningococcal infection (Oliver et al. 2002). 
2.5 Search for serological correlates of protection 
Besides SBA assay, a variety of other techniques, such as opsonophagocytic (Aase et al.
1998, Naess et al. 1999) and whole-blood assays for functional antibodies (Morley et al.
2001), non-functional assays (Naess et al. 1998, Perez et al. 2001, Wedege et al. 2003), and 
assessment of active (Sifontes et al. 1997) or passive protection in animal models (Infante et 
al. 1994) have been evaluated for providing additional information about the mechanisms of 
protective immunity or even for providing better correlates for efficacy of serogroup B 
meningococcal vaccines.   
2.5.1 Assays to measure immunity to serogroup B meningococcus
Of the non-functional assays, the enzyme immunoassays (EIA) have been most widely used 
to determine not only the magnitude and persistence but also the isotype distribution of anti-
meningococcal antibodies. Both OMVs containing multiple OM antigens and purified OMPs, 
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LOS, or capsular PS have been used as the coating antigen. In several studies, relatively good 
correlations between anti-OMV IgG levels and SBA titers have been found (Rosenqvist et al.
1988, Aase et al. 1995, Rosenqvist et al. 1995, Naess et al. 1999) while in others, only poor 
association between these two assays have been detected (Milagres et al. 1994, Boslego et al.
1995), probably reflecting the great variety how these methods are performed in different 
laboratories. A multi-laboratory evaluation of both assays would be needed to establish the 
reason for these discrepancies.  
Besides antibody quantity and isotype, there is strong evidence that also other qualitative 
characteristics of antibodies, namely their avidity, may be important to protection against 
meningococcal disease (Harris et al. 2003a, Welsch and Granoff 2004). Recently, a modified 
EIA, using sodium thiocyanate as a chaotropic agent, has been described to measure the 
avidity of anti-OMV antibodies (Longworth et al. 2002, Vermont et al. 2002). Due to scarcity 
of studies measuring avidity indices (Longworth et al. 2002, Vermont et al. 2002, Vermont et 
al. 2004), its value as a marker of protective activity and immunological memory following 
serogroup B OMV vaccination remains to be established.   
While being of great value for the detection of antibody kinetics following OMV vaccination, 
the EIAs do not provide information about the specificity of antibodies induced unless well-
defined, purified proteins or other surface structures in right conformation are used as the 
target antigens. Thus, to get a more thorough picture about specificity of antibodies, an 
immunoblotting method capable of discriminating antibody binding to different OM antigens 
(OMPs and LOS) is needed (Wedege and Froholm 1986, Wedege et al. 1998). Due to 
denaturizing conditions during antigen preparing, a duplicate sample treated with appropriate 
detergent to partially refold the proteins and hence, to detect antibody binding also to 
conformation-dependent epitopes, is generally included (Wedege et al. 1988). In sera from 
patients and vaccinees antibody responses to several OM antigens are generally detected 
(Wedege and Froholm 1986, Rosenqvist et al. 1995, Wedege et al. 1998, Wedege et al.
2000). Following three doses of the Norwegian serogroup B OMV vaccine, antibody to class 
1, class 5, 80kDa protein and LOS all contributed significantly to SBA against the vaccine 
strain (Rosenqvist et al. 1995). 
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Of the functional assays, the SBA has most widely used to assess antibody responses in large 
clinical trials. In this assay, meningococci are incubated with human sera in the presence of 
suitable human or, if applicable, animal complement, and the bactericidal activity of serum 
expressed as the reciprocal of serum dilution yielding ? 50% or 90% killing as compared to 
the number of target cells present before incubation with serum and complement. As the 
species of complement source may greatly affect the SBA titers (Zollinger and Mandrell 
1983), for serogroup B SBA assay human complement is strongly recommended. By contrast 
to serogroup A and C SBA assays (Maslanka et al. 1997), the serogroup B SBA assay has not 
been standardized yet and slightly different protocols are used in different laboratories. This 
makes the inter-laboratory comparisons somewhat complicated. Since the seminal work of 
Goldschneider et al. (Goldschneider et al. 1969a, Goldschneider et al. 1969b), a SBA titer of 
4 has been generally used as the threshold of protection. Most studies, however, have not 
relied on absolute SBA titers as a cut off but instead used ? 4-fold rise in SBA titer compared 
to pre-vaccination level to estimate the potential efficacy of serogroup B meningococcal 
vaccines. There is some evidence that SBA assay correlates with serogroup B OMV vaccine 
efficacy (Milagres et al. 1994, Boslego et al. 1995, Holst et al. 2003). However, further 
studies using SBA as a marker of OMV vaccine responses are required to gain a more 
comprehensive view of the value of this assay as predictor of both natural and serogroup B 
vaccine induced immunity. 
In addition to SBA, it has been suggested that also OPA is an important defense mechanism 
against meningococcal infections, especially those caused by serogroup B organisms (Ross et 
al. 1987), and a variety of techniques have been developed to measure this activity. In these 
assays, live or killed bacteria are first opsonized with human sera in the presence or absence 
of endogenous or exogenous complement source. After incubation with effector cells, usually 
freshly isolated human PMNLs, the amount of phagocytosis is measured by viable counts 
(Schlesinger et al. 1994), flow cytometry (Sjursen et al. 1989, Lehmann et al. 1998) or 
chemiluminescence (Halstensen et al. 1989, Sjursen et al. 1992). Increased OPA against 
meningococci of different serogroups has been detected following vaccination and disease 
(Roberts 1970, Halstensen et al. 1984, Sjursen et al. 1987, Halstensen et al. 1989, Schlesinger
et al. 1994, Lehmann et al. 1999). 
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A whole blood assay (WBA) has also been developed to measure the total killing capacity of 
human blood after infection or vaccination (Ison et al. 1995, Ison et al. 1999). In this assay 
heparinized venous blood collected from subjects is inoculated with meningococci, and after 
incubation, the percentage of bacterial killing given relatively to initial bacterial load. It has 
been suggested that this assay is more sensitive than the SBA, with WBA activity detected in 
some individuals lacking SBA (Ison et al. 1999). However, the WBA is unlikely to be 
suitable for large scale evaluation of clinical samples because of the requirement for large 
volumes of fresh blood and difficulties in the standardization of the assay.  
2.5.2 Animal models of meningococcal infection 
An alternative mean to study the protective efficacy of existing and candidate vaccines would 
be an animal model, in which the protection would depend on the same effector mechanisms 
as in human disease. Such a model should cover both the complement-mediated killing of the 
bacteria and their phagocytosis, as well as complex interactions of multiple humoral and 
cellular factors of the host.  
Since the first isolation of causative agent of meningococcal meningitis at the late 19th 
century, a variety of animal species from chicken embryos to monkeys and different routes of 
infection (intranasal, intraperitoneal, and intrathecal) have been tried to establish a 
reproducible experimental meningococcal disease in animals, with varying success (reviewed 
in (DeVoe 1982, Arko 1989)).  Of the animal models evaluated, the mouse model requiring 
exogenous iron load (Gorringe et al. 2001) and the infant rat model without enhancers 
(Saukkonen 1988) have proven most useful and used widely for active and/or passive 
protection studies.  
Mouse models 
Since its first description in 1933 (Miller 1933), the iron-dependent mouse infection model 
with intraperitoneal (i.p) bacterial inoculation has survived with only minor modifications to 
the present time. In this model, log-grown meningococci are mixed with exogenous iron 
source to enhance bacterial virulence, originally hog gastric mucin (Miller 1933), later iron 
dextran (Holbein et al. 1979) or human transferrin  (Holbein 1981a), and 105-107 colony 
forming units (cfu) of appropriate organisms injected i.p. to 6-8 weeks old mice (Gorringe et 
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al. 2001). This model seems to detect differences in virulence between carrier and disease 
strains (Holbein et al. 1979, Holbein 1981b) and has been used widely in active (Sifontes et 
al. 1997, Oftung et al. 1999) and passive (Moreno et al. 1983, Brodeur et al. 1985, Perez-
Ramirez et al. 1997) immunization studies. In protection studies, reduction in mortality rates 
and/or bacteremia levels has been used as the end point.  
Mouse colonization models with intranasal (i.n.) inoculation of infant (Salit et al. 1984, 
Mackinnon et al. 1992) or adult mice (Yi et al. 2003) have also been described. In these 
models meningococci are mixed with exogenous iron source and 107-1010 cfu of appropriate 
organisms given i.n. to mice; an i.p. injection of iron dextran is given prior to and after 
infection to further enhance infection. While i.n. models appear useful for studying the early 
pathogenesis of infection and the role of mucosal immunity, they are less suitable for large-
scale assessment of protection because of the low and variable rate of invasive disease despite 
consecutive iron injections. Further, by contrast to human host, a preceding lung colonization 
was necessary for the development of bacteremia (Mackinnon et al. 1992). 
More recently, an i.n. mouse model without exogenous iron supplementation has been 
described. In this sequential, influenzae A virus (IAV)-N. meningitidis serogroup C infection 
model, adult BALB/c mice are infected i.n. with mouse-adapted IAV, followed by co-
infection with meningococci seven days later (Alonso et al. 2003). Fatal meningococcal 
pneumonia and bacteremia occurred in mice challenged at seven but not ten days after IAV 
infection. Susceptibility to lethal infection correlated with IAV induced peak in interferon-?
production, suggesting that transient IAV-induced modulation of host innate immunity 
predisposed mice to systemic meningococcal infection (Alonso et al. 2003).  
To more accurately mimic host-pathogen interaction in the human host, a meningococcal 
infection model in transgenic mice expressing human CD46 with human-like tissue 
specificity (Mrkic et al. 1998) has been recently developed (Johansson et al. 2003). As 
described earlier, in the human host, the expression CD46 is thought to be essential for 
meningococcal virulence by serving as a receptor for pilus-mediated attachment of 
encapsulated meningococci to epithelial and endothelial cells of nasopharynx and blood-brain 
barrier (Källström et al. 1997). While clearly enhancing the development of bacteremia and 
meningitis following i.p. infection, after i.n. infection with piliated serogroup W135 
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meningococci only a slight although significant increase in mortality rates was observed, with 
15% (4/27) of the CD46 transgenic mice compared to none (0/27) of the non-transgenic 
C57BL/6 mice used as the control succumbing to infection. Expression of pili was necessary 
for the virulence of bacteria as non-piliated isogenic strain caused no signs of disease in either 
mouse strain. Though the colonization rates were not reported, the authors suggested that this 
only relatively modest increase in mortality rates was due to the expression of CD46 mainly 
on the basolateral rather than apical surface of the respiratory epithelial cells (Johansson et al.
2003), and hence, opposing the situation in the human host (Varsano et al. 1995, Sinn et al.
2002). Pre-treatment of animals with antibiotics to diminish normal bacterial flora prior to i.n. 
inoculation was also necessary, all un-treated CD46 transgenic mice surviving infection. 
While having potential as a more natural model for human infection, an increase in infection 
rate is clearly needed for protection studies.  
The major advantage of mouse models is that a number of different inbred strains with 
deficiencies in innate and adaptive immunity are available to elucidate host-pathogen 
interactions and the mechanisms protection. However, due to extremely low lytic activity of 
mouse serum relative to humans and rats (Ong and Mattes 1989), and the multiple effects of 
both iron overload (Mencacci et al. 1997, Hor et al. 2000, Walker and Walker 2000) as well 
as dextran (Sahu et al. 1994) on phagocyte and complement function, the relevance of mouse 
models for assessment of protection remains to be fully elucidated.   
Infant rat model 
With the success in establishing reproducible infection models for other encapsulated gram-
negative bacteria in infant rats, namely Haemophilus influenzae type b and Escherichia coli
K1, efforts to develop such model also for meningococci began at KTL in late 1980’s, with 
successful results (Saukkonen 1988).  
In this model, 103-107 cfu of log grown organisms are injected intraperitoneally to 5-7 day-old 
infant rats, and the development of bacteremia and meningitis is followed by cultivating blood 
and cerebrospinal fluid samples taken at appropriate time-points (Saukkonen 1988, Welsch et 
al. 2003). Meningococci of all the major serogroups A, B, and C, are infective (Saukkonen 
1988, Welsch and Granoff 2004, Welsch et al. 2004). The course of infection is reproducible 
and predictable: a localized peritoneal inflammation is followed by invasion of the bacteria 
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into the bloodstream. The outcome of disease varies from transient bacteremia to lethal 
bacteremia and meningitis depending on the challenge strain and dose used (Saukkonen 
1988). Importantly, no artificial enhancing factors such as mucin or iron compounds that may 
have multiple and poorly definable effects on both the bacteria and the host are needed. 
Though the short period of susceptibility of infant rats to infection (Salit et al. 1984) prevents 
active immunization studies, a large litter size (8-12 pups/litter) guarantees the availability of 
a large number of animals for short-term experiments such as the passive immunization 
studies. Later on, the model has been successfully used to identify antigens involved in 
protection and also to test the protective activity of antibodies elicited by candidate vaccines 
(Saukkonen et al. 1987, Saukkonen et al. 1989, Idänpään-Heikkilä et al. 1995, Welsch et al.
2003, Welsch et al. 2004). Like in mouse protection studies, reduction in mortality rates 
and/or bacteremia levels has been used as the assay end points.
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3 AIMS OF THE STUDY 
An important question for vaccine development was whether the infant rat infection model 
could also be used to test the protective activity conferred by human immune sera collected 
after OMV vaccination, and thus, as a surrogate assay for serogroup B OMV vaccine efficacy. 
Such a use would need careful validation of the assay conditions for sensitivity and 
repeatability. In the search for vaccine candidates against serogroup B disease, the specificity 
and the functional activity of natural antibodies has been less studied. Relatively little was 
also known about the in vivo functional activity of antibodies of different specificity or 
isotype. To this end, the aims of this thesis were:  
- to adapt and standardize the infant rat protection assay for the evaluation of human 
sera for protective immunity to group B meningococci (I, II) 
- to assess the reproducibility of the infant rat protective activity (IRPA) assay (I, II) 
- to assess IRPA of sera taken before and after vaccination of Icelandic teenagers with 
the Norwegian and the Cuban serogroup B meningococcal OMV vaccines, and to 
compare the results of the IRPA assay to those obtained by SBA assay and anti-OMV 
EIA (II) 
- to assess the specificity and functional activity of natural antibodies responsible for 
IRPA against 44/76-SL strain (III) 
- to assess the influence of antibody specificity (capsular versus sub-capsular antibody), 
isotype, and the importance of complement-mediated bacterial lysis on protection in 
the IRPA assay (III, IV) 
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4 MATERIALS AND METHODS 
4.1 Serum samples and monoclonal antibodies used in IRPA assays 
In study I, three post-vaccination sera collected from adult volunteers vaccinated twice with 
the Norwegian meningococcal serogroup B OMV vaccine (Bjune et al. 1991b) and one 
normal human serum from an unvaccinated person with no history of meningococcal disease 
were used. These sera were selected from a large panel of sera available at the Norwegian 
(formerly National) Institute of Public Health (Einar Rosenqvist, NIPH, Oslo, Norway). 
In study II, pre- and post-vaccination serum samples from 92 teenagers who had received two 
doses of either the Norwegian OMV vaccine (B:15:P1.7,16), the Cuban OMV vaccine 
(B:4:P1.19,15), or the serogroup A/C capsular PS control vaccine (Aventis Pasteur, Lyon, 
France) during a previous immunogenicity trial in Iceland (Perkins et al. 1998) were used. Of 
the 92 study participants, 20 (22%) had received the control (A/C), 37 (40%) the Norwegian, 
and 35 (38%) the Cuban vaccine. The sera were selected at the Centers for Disease Control 
and Prevention (Brian Plikaytis, CDC, Atlanta, GA) by criteria described (II) to represent a 
25% sample of vaccine responders and non-responders in the original study (Perkins et al.
1998). Serum samples were sent frozen to National Public Health Institute (KTL, Helsinki, 
Finland) from CDC and stored at -20°C until analyzed. 
In study III, a representative set (26/92; 28%) of pre-vaccination sera from Icelandic teenagers 
(Perkins et al. 1998) with convergent or divergent IRPA and SBA data (II) against strain 
44/76-SL was used. The sera were selected on the basis of the availability of > 0.2-ml 
volumes and analyzed for functional and specific antibodies as described. In addition, in study 
III, normal human sera (NHS; n=20) collected from healthy Finnish children of four different 
age groups (7, 14 and 24 months, and 10 years) were used. These sera had been collected in 
connection with previous immunogenicity studies (Mäkelä et al. 2003) and stored frozen at –
20°C until used. Informed consent and approvals from the ethics committees covered the use 
of these sera in this study. 
In study IV, a panel of mouse-human chimeric Mabs of all the four human IgG subclasses 
(IgG1-4) with identical variable genes against the P1.16 epitope on the PorA protein 
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(Vidarsson et al. 2001) were used. The production and in vitro characteristics of these 
antibodies have been described elsewhere (Vidarsson et al. 2001). The parental mouse P1.16 
specific IgG2a antibody MN12H2 (Jiskoot et al. 1991) was received from Betsy Kuipers 
(NVI, Bilthoven, The Netherlands). 
The B-PS specific IgG2a antibody Nmb735 (formerly Mab735) (Frosch et al. 1985) was a 
gift from H-P Harthus (Dade Behring, Marburg) and was used as a positive control for 
protection (dose of 2 μg/pup) throughout the IRPA studies (I-IV).  
4.2 Depletion of B-PS specific antibodies 
NHS collected from healthy Finnish children were absorbed with aluminum hydroxide gel 
(Alhydrogel 2%, Brenntag Biosector, Denmark) bound B-PS to deplete B-PS specific 
antibodies as described (III).  
4.3 Bacterial strains and growth conditions 
Three N. meningitidis strains were used. Strain IH5341 (I) was a cerebrospinal fluid isolate of 
a human patient and had the phenotype of B:15:P1.7,16 (Käyhty et al. 1989). The mother 
strain 44/76 (II, III, IV) for the Norwegian OMV vaccine (Fredriksen et al. 1991) (44/76-SL) 
was first isolated by Holten from a fatal case of meningococcal disease (Holten 1979) and had 
a phenotype of B:15:P1.7,16. The Cuban vaccine strain Cu385 (II, III) was their local clinical 
isolate and had a phenotype of B:4:P1.15 (Sierra et al. 1991). 
For IRPA studies (I-V), the strains were rat-passaged (Saukkonen 1988) 3-5 times and stored 
in skimmed milk at -70°C. In SBA assays performed at KTL (III, IV), rat-passaged 44/76-SL 
strain was used. In other assays, including SBA (I, II, III) and OPA (I, III) assays performed 
elsewhere, un-passaged strains were used. The expression of different surface antigens in un-
passaged and rat-passaged 44/76-SL and Cu385 strains was verified by SDS-gels performed 
at NIPH and whole-cell EIAs preformed at KTL (Toropainen et al. 2001) with monoclonal 
antibodies described below.  
Inoculum for IRPA and SBA assays performed at KTL was prepared from broth-grown, early 
log phase bacteria essentially as previously described (Saukkonen 1988). Inoculum SBA and 
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OPA assays performed elsewhere was prepared from plate-grown, log-phase bacteria as 
described (I (Høiby et al. 1991), II, III (Perkins et al. 1998), III (Aase et al. 1998). 
4.4 Monoclonal antibodies used for strain characterization 
Monoclonal antibodies used for bacterial strain characterization are listed in Table 2. 
Table 2. Monoclonal antibodies (Mab) used for bacterial strain characterization. 
Mab Specificity Source 
Mab 95/750 Group B PS NIBSC 
8B55G9 Serotype P3.15 NIBSC 
MN14G21 Serotype P3.4 NIBSC 
MN14C11.6 Serosubtype P1.7 NIBSC 
MN3C5C Serosubtype P1.15 NIBSC 
MN5C11G Serosubtype P1.16 NIBSC 
MN4A8B2 L3,7,9 NVI 
MN43F8.10 L8 NVI 
154,D-11 OpcA NIPH 
NIBSC, National Institute for Biological Standards and Control, Potters Bar, UK 
NVI, Netherlands Vaccine Institute, Bilthoven, The Netherlands 
NIPH, Norwegian Institute of Public Health, Oslo, Norway 
4.5 Whole-cell EIA 
Whole-cell EIA was performed at KTL as described (Toropainen et al. 2001) using heat 
inactivated (56 ºC, 30 min) bacteria as coating antigen and peroxidase-conjugated rabbit 
antibodies to mouse immunoglobulins as the second antibody (Dako A/S, Denmark). 
4.6 OMV EIA 
IgG antibodies to strain IH5341 (I) were measured by EIA as described (Idänpään-Heikkilä et 
al. 1995) using a meningococcal capsular PS-depleted whole-cell preparation of strain 
IH5341 as the coating antigen and peroxidase-conjugated rabbit antibodies to human 
immunoglobulin G (IgG) as the second antibody (Dako A/S, Denmark). The results were 
expressed as titers, i.e. reciprocals of serum dilutions giving an optical density (O.D.) of 0.3 
measured at 450 nm. 
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Anti-OMV IgG antibody concentrations for the Icelandic study sera (II, III) were obtained 
from B.D. Plikaytis. As reported previously (Perkins et al. 1998), these data were obtained at 
the NIPH and the Finlay Institute, respectively, using OMVs from their respective vaccine 
preparations as solid-phase antigen in their OMV EIA (Rosenqvist et al. 1991, Ferriol 
Marchena et al. 1999). The results were expressed as arbitrary units (U/ml). A vaccine 
responder was defined as an individual with a ? 4-fold and a non-responder as an individual 
with a < 4-fold rise in anti-OMV IgG level. 
4.7 B-PS EIA 
Antibodies to meningococcal group B capsular polysaccharide (B-PS) (III) were measured by 
EIA essentially as described previously (Arakere and Frasch 1991), using B-PS non-
covalently complexed to methylated human serum albumin as coating antigen and 
peroxidase-conjugated rabbit antibodies to human immunoglobulin IgG or IgM (Dako A/S, 
Denmark) as the second antibody. The results were expressed as titers, i.e. reciprocals of 
serum dilutions giving an O.D. of 0.3 measured at 450 nm. The sera were assayed starting at 
1:50 dilution. Negative samples were assigned a titer of 1:10. 
4.8 SBA assay 
SBA data for the sera received from the NIPH (I) were obtained from E. Rosenqvist (NIPH) 
and for the Icelandic sera (II and III) from Dr. B.D. Plikaytis (CDC). SBA was measured at 
the NIPH (Høiby et al. 1991) and CDC (Perkins et al. 1998) according to their SBA assay 
protocols, respectively, using 25% human plasma as the exogenous complement source.  
SBA of sera from Finnish children (III) or monoclonal antibodies (IV) were determined at 
KTL using human serum from an individual without bactericidal antibodies to strain 44/76-
SL (III, IV) or serum from 5-6 day-old HsdCpb:WU (III), HsdBrlHan:WIST (IV) or 
PVG/OlaHsd (IV) rat pups (Harlan, The Netherlands) as exogenous complement source at a 
final concentration of 20%.  
The results were expressed as the reciprocal of the highest serum dilution giving 50% killing 
of the inoculum (I, II, III) or the lowest antibody concentration giving 90% killing of the 
inoculum (IV). Sera with titer of <4 were considered SBA negative and those with titer of ?4
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SBA positive (I-III). A vaccine responder was defined as an individual with a ? 4-fold and a 
non-responder as an individual with a < 4-fold rise in SBA titer. 
4.9 OPA assay  
OPA (I, III) was measured at NIPH as respiratory burst (RB) by flow cytometry with 
polymorphonuclear leukocytes (PMNLs) as the effector cells and ethanol fixed (I) (Aase and 
Michaelsen 1994) or live 44/76-SL cells grown on plates to log phase (III) (Aase et al. 1998) 
as the target cells. Human serum without any antibody activity against the target strain was 
used as complement source at a final concentration of 10%. The percentage of effector cells 
that had undergone RB was determined, and the results expressed as the reciprocal of the 
highest serum dilution giving RB above the cut-off line of 15% cells. Sera with titer of < 2 
were considered OPA negative and those with titer of ? 2 OPA positive. 
4.10 Quantification of IgG by flow cytometry 
Anti-meningococcal IgG antibodies were quantified (III) at NIPH with live, log grown 44/76-
SL cells by flow cytometry as described (Aase et al. 1998). Two-fold dilutions of a reference 
plasma (quantified by EIA against OMVs) was used as an internal standard to create a 
standard curve with concentration (range 0.07-9.0 mg/ml) on the abscissa and median 
fluorescence intensity (MFI) on the ordinate to which the MFI of test samples were 
interpolated.   
4.11 Immunoblotting 
Immunoblotting (I and III) was carried out at NIPH as described (Wedege et al. 1998) with 
deoxycholate extracted OMVs (Fredriksen et al. 1991) from strain 44/76-SL as antigen. Strips 
loaded with OMV antigens were incubated with 1:200 dilutions of human sera in the absence 
and presence of 0.15% Empigen BB to detect antibody binding to conformation-dependent 
epitopes (Wedege et al. 1988). The intensities of IgG binding to different OMV antigens 
[Omp85, FetA (FrpB of mol.wt. 70 kDa), P1.7,16 PorA, P3.15 PorB, Rmp (class 4 protein), 
OpcA, OpaJ (class 5.5 protein), LOS of immunotypes L3 and L8, and unidentified antigens 
with higher mol. wt. around 50 kDa (HMW) or in the lower range 20-25 kDa (LMW)] were 
determined visually. By visual determination, the immunoreactive bands were scored on a 
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scale from 0 to 4, where scores between 0 and 1.5, between 2 and 2.5, and between 3 and 4 
represented no or weak binding, medium binding, and strong binding, respectively.  
4.12 Experimental animals 
In passive protection studies, 4-7 days old, outbred albino Wistar rat pups (HsdCpb:WU or 
HsdBrlHan:WIST) and inbred PVG (PVG/OlaHsd) rat pups with normal (designated 
PVG/c+) or C6 deficient complement (designated PVG/c-) were used.  
HsdCpb:WU rats (I, II, III) were purchased as specific pathogen-free from Harlan Nederland 
(Horst, The Netherlands), bred locally at the Helsinki University Animal Centre (Helsinki, 
Finland) up to 3 generations until timed-mated to get the litters, and allowed to deliver in the 
animal facilities of KTL. 
For study IV, timed-pregnant female HsdBrlHan:WIST and PVG/OlaHsd rats were purchased 
from Harlan Nederland (Horst, The Netherlands) and allowed to deliver in the animal 
facilities of KTL. Conventionally bred complement component C6 deficient PVG rats 
(designated PVG/c-) (Leenaerts et al. 1994) were received from M.R. Daha (Department of 
Nephrology, Leiden University Medical Center, Leiden, The Netherlands). They were 
subsequently purified by hysterectomy, propagated up to 5 generations until timed-mated to
get the litters and allowed to deliver in the animal facilities of KTL. 
As the effect of C6 deficiency on bacterial virulence in non-immune infant rats was not 
known, in preliminary studies several challenge doses (102 to 106 cfu/pup) of strain 44/76-SL 
were tested and the resulting bacteremia levels (cfu/ml) in C6 deficient PVG/c- rats were 
compared to those of complement sufficient HsdBrlHan:WIST and PVG/c+ rats. No 
significant differences between complement sufficient and C6 deficient rats were found.  
4.13 Infant rat protection assay 
The passive protection experiments (I-IV) were done as described previously (Saukkonen 
1988). In brief, 4-7-day-old rat pups (average weight 12 g) were randomly redistributed in 
groups of 5-6 animals and injected intraperitoneally (i.p.) with appropriately diluted, heat-
inactivated (56ºC, 30 min) human serum or monoclonal antibodies, in a final volume of 0.1 
ml. Saline served as a negative and a monoclonal mouse antibody Nmb735 to serogroup B PS 
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(Frosch et al. 1985) as the positive control for protection. One to two hours later a bacterial 
challenge of 104 to 107 cfu/pup was injected i.p. in a final volume of 0.1 ml. Development of 
meningitis (I) and/or bacteremia (I-IV) was assessed by culturing blood and cerebrospinal 
fluid (CSF) samples taken at appropriate time-points after bacterial challenge. The limit of 
detection was 1×102 and 1×103 cfu/ml for CSF and blood cultures, respectively. Animals with 
sterile cultures were assigned a value of 0.3× the detection limit, i.e. 30 and 3×102 cfu/ml for 
CSF and blood cultures, respectively.  
In all studies (I-IV), reduction in bacteremia levels was used as the main protection assay end-
point. In studies II and III, a protection index (PI) was generated based on the reduction in 
geometric mean concentration (GMC) of bacteria in blood (cfu/ml). PI was equivalent to fold 
decrease in GM cfu/ml in each experimental group of animals relative to the control group of 
the same day. For each serum PI was calculated as follows: GM cfu/ml for control animals / 
GM cfu/ml for serum treated animals. Sera with PI < 1 were assigned a value of 1. A PI of 10 
(i.e. a 10-fold reduction in GM cfu/ml blood in the experimental group compared to the 
control group) was used as cut-off value of protective activity. Thus sera with PI <10 were 
considered IRPA negative and those with PI ?10 IRPA positive. A vaccine responder was 
defined as an individual with at least 10-fold rise in PI (post-vaccination serum PI/pre-
vaccination serum PI). 
All experimental protocols were reviewed by the Institutional Laboratory Animal Committee 
and finally approved by the Provincial Board. 
4.14 Statistical methods 
In statistical analysis, log transformed data was used. For inter- and intra-assay comparisons, 
the data were subjected to one-way analysis of variance (SPSS Inc., Chicago, Illinois). 
Statistical differences between GMs (or fold-increases in GMs) in different groups were 
calculated with two-tailed t test assuming equal variances, and differences between pre- and 
post-vaccination GMs with paired-samples t test. Pearson correlation coefficients were 
calculated with SPSS software. Fisher’s exact test was used to analyze differences in vaccine 
responder rates (SPSS). For all comparisons, a P value of ?0.05 was considered significant. 
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5 RESULTS
5.1 Adaptation of IRPA assay for use with human sera (I) 
For a large-scale evaluation of clinical samples, a sensitive and repeatable assay is needed.  
Thus, our first aim was the adaptation and standardization of the infant rat protective activity 
(IRPA) assay for use with human sera (I), paying special attention to the choice of challenge 
dose and serum dilution used.  
5.1.1 Choice of challenge dose 
In preliminary studies, several challenge doses (104-107 cfu/pup) of strain IH5341 
(B:15:P1.7,16) were tested, and the development of bacteremia and meningitis was monitored 
in rat pups (6 animals/group) pre-injected with either saline (control group) or with a 
monoclonal antibody to the group B capsular polysaccharide (Nmb735) used as a positive 
control for protection.   
The dose of 104 cfu/pup did not result in a satisfactory development of either bacteremia or 
meningitis. Only half of the animals in the control group (3/6) were bacteremic at six hours. 
The GMC of bacteria in the blood was 9.2×103 cfu/ml; none of the animals developed 
meningitis (I; figure 1). Prolonging the experiment overnight did not increase the infection 
rate: three of the six animals were bacteremic and only one had bacteria in the CSF. All 
subsequent experiments were terminated at six hours, like in previous studies (Nurminen et 
al. 1992, Idänpään-Heikkilä et al. 1995). 
With the higher challenge doses of 105 to 107 cfu/pup, all saline treated animals were 
bacteremic at six hours (I; figure 1). The bacterial counts in the blood increased with 
increasing challenge dose from a GMC of 5.7×105 cfu/ml with the dose of 105 to 2.3×107
cfu/ml with the dose of 107. These higher bacterial loads also resulted in high rates of 
meningitis, varying from 67 to 100% (I; figure 1). However, with the highest dose the 
sensitivity of the detection of protection decreased. Although highly protective against 
challenge doses of 104-106 bacteria, the Nmb735 failed to show any IRPA against challenge 
with 107 meningococci. On the basis of these results, doses of 105 and 106 cfu/pup were 
selected for subsequent studies with human sera.  
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5.1.2 Choice of serum dilution 
Four sera, three collected from adults immunized with the Norwegian serogroup B 
meningococcal OMV vaccine and one from a non-vaccinated person with no history of 
meningococcal disease, were used for adaptation of the IRPA assay for use with human sera. 
The sera were first tested at the dilution of 1:10, and then, if protective, at dilutions of 1:30 
and 1:100. Most assays were repeated once or twice in separate experiments with a different 
batch of animals to assess the repeatability of the assay.  
As in preliminary experiments, the development of bacteremia and meningitis in saline 
treated control animals was highly constant with both challenge doses. The non-immune 
serum had low activity in EIA measuring IgG antibodies to sub-capsular antigens and 
negligible reaction in immunoblots; it showed no functional activity in vitro in SBA assay or 
OPA assay. When tested for protective activity against a challenge dose of 105 in the IRPA 
assay, the rates of bacteremia were the same as in the control animals in both experiments at 
the serum dilution 1:10 and the one experiment at dilution 1:30. In one experiment, at dilution 
of 1:10, the bacterial counts in the blood were reduced to 6.5% (P = .03) of the value in the 
control group, and there was also a reduction in the rate of meningitis. However, in the other 
experiments at serum dilutions 1:10 and 1:30 there was no indication of protective activity (I; 
Table 2). Against the higher dose of 106, no protective activity was detected (I; Table 3). 
The post-vaccination sera were, as a rule, protective in the IRPA assay and their IRPA could 
be further quantified by testing different serum dilutions and by varying the challenge dose. 
With the challenge dose of 105, all the three post-vaccination sera were IRPA positive at 1:10 
and 1:30 dilutions, whereas the dilution 1:100 gave no protection (I; Table 2). With the higher 
dose of 106 cfu/pup, two sera were IRPA positive at 1:10 dilution; one was still protective at 
the 1:30 dilution (I; Table 3). These two sera also had the highest SBA titers (1:32 and 1:64) 
and one of them high but the other one moderate OPA (1:128 and 1:32). By contrast, the 
serum with low SBA (1:4) but high OPA (1:64) failed to reproducibly show IRPA against the 
higher challenge dose of 106 cfu/pup. In one experiment, at dilution of 1:10, the bacterial 
counts in the blood were reduced to 3.8% (P <0.05) of the value in the control group, and 
there was also a reduction in the rate of meningitis. However, in the other two experiments at 
dilution 1:10 and in the three experiments at dilution 1:30 there was no indication of IRPA (I; 
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Table 2). Thus, similar to results obtained with group B capsular specific Mab Nmb735, with 
the higher challenge dose of 106 cfu/pup the sensitivity of IRPA assay to detect protection 
decreased.   
The sensitivity of IRPA assay varied also depending on the criterion used. With the challenge 
dose of 106 (I; table 3), a statistically significant reduction in the rate of bacteremia was seen 
in only 63% (5/8) of cases in which the GMC of bacteria in the blood was significantly 
reduced. For the dose of 105 (I; Table 2), this proportion was even lower (54%, 7/13). When 
the rate of meningitis was compared with GMC of bacteria in the blood, highly consistent 
results were obtained in terms of protection: when the serum prevented the development of 
bacteremia, it also inhibited meningitis. However, because of small number of animals per 
experimental groups (n=6) and, for the challenge dose of 105, a relatively low rate of 
meningitis even in the saline treated control animals (3/6-4/6), the reductions in the rates of 
meningitis rarely reached statistical significance (P < .05). Therefore, for sensitivity, the most 
relevant parameter of protection appeared to be the reduction in the bacteremia level.  
A strong positive correlation between blood and CSF bacterial counts in both saline and 
serum treated animals was observed, suggesting that the bacterial concentration in the blood 
was the direct determinant of their penetration to the CSF. If there were ?107 bacteria in the 
blood, all animals had bacteria in the CSF. Vice versa: when the bacteremia level was <104
cfu/ml, the CSF was always culture-negative (I; Fig. 2). 
We concluded that IRPA assay was entirely feasible for use with human sera, warranting 
further studies with a larger serum set from a clinical trial. Using bacteremia level as the 
IRPA assay endpoint, a serum dilution of 1:10 combined with a bacterial dose of 105 cfu/pup 
seemed the most optimal choice in terms of assay sensitivity.   
5.2 Assay reproducibility (I, II)  
The reproducibility of the IRPA assay is of major importance for large-scale studies. This was 
assessed by analyzing the repeatability of bacteremia in saline treated control group animals 
in each of the total of 42 passive protection experiments conducted with the Norwegian 
vaccine strain 44/76-SL and 29 experiments conducted with the Cuban vaccine strain Cu385 
(II).
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For both strains, bacteremia levels remained similar throughout the whole one-year and nine-
month study period (II; Fig. 1). All (n=252) control animals were bacteremic 6 hrs after i.p. 
challenge of approximately 106 cfu/pup with strain 44/76-SL (GM 5.6×106, range 1.7-
8.2×106). The bacteremia levels ranged from 8.7x104 to 1.1x107 cfu/ml with a GM of 1.1×106
cfu/ml (95% CI 0.8-1.6×106) and coefficients of variation (CV) of 15% (range 5-27%) for 
intra-assay and 21% for inter-assay comparisons. After a similar challenge dose (GM 7.2×106,
range 5.8-9.3×106) with strain Cu385, 83-100% of the control animals were bacteremic after 6 
hrs. The bacteremia levels ranged from 3.8×104 to 3.0×106 cfu/ml with a GM of 2.3×105
cfu/ml (95% CI 1.6-3.3×105) and CV of 15% (range 2-30%) for intra-assay and 19% for inter-
assay comparisons. Thus, similar to the smaller study (I), the reproducibility of IRPA assessed 
by the development of bacteremia in saline-treated control animals, was found satisfactory. 
This held generally true also for reproducibility of the protection assays but in 2 cases out of a 
total of 12, the results of the protection assays, using at least 10-fold reduction in GM 
bacteremia level as the criterion of protection, were contradictory (I).  
5.3 Serogroup B OMV vaccine responses in IRPA assay (II) 
To assess the value of IRPA assay as a correlate of OMV vaccine induced protection in 
humans, a large-scale evaluation of clinical samples was needed. To this end, pre- and post-
vaccination serum samples taken from 92 teenagers who had received two doses of either the 
Norwegian OMV vaccine, the Cuban OMV vaccine, or the serogroup A/C capsular PS 
control vaccine during a previous immunogenicity trial in Iceland (Perkins et al. 1998) were 
analyzed for IRPA and the results compared to SBA and anti-OMV IgG data obtained earlier 
elsewhere (Perkins et al. 1998).  
In each of the total of 71 passive protection experiments, 1 to 5 paired samples, i.e. sera taken 
before immunization and six weeks after the second immunization, were assayed for IRPA in 
an experimental unit of six animals/serum. Based on our earlier study (I), 1:10 serum dilution 
was used. IRPA was defined as fold decrease in geometric mean (GM) cfu/ml blood in each 
experimental group of animals relative to the control group of the same day, expressed by 
protection index (PI). A PI of 10 was used as a cut-off value of protective activity, and a 
vaccine responder defined as an individual with at least 10-fold rise in PI compared to pre-
vaccination level. All sera were tested against both the Norwegian (44/76-SL, B:15:P1.7,16) 
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and the Cuban (Cu385, B:4:P1.19,15) vaccine strain as in previous SBA and EIA studies 
(Perkins et al. 1998).
5.3.1 Selection of challenge dose 
As the adaptation of the IRPA assay for human sera had been done using another strain (I), a 
series of preliminary experiments was carried out to adjust the assay conditions for 44/76-SL 
strain and Cu385 strain that had been previously used in SBA assay (Perkins et al. 1998). To 
this end, both strains were first rat-passaged three times and the reproducibility of bacteremia 
assessed in rat pups (6 animals / group) at six-hour post-infection with 105 to 107
meningococci. As in the previous study, saline was used as the negative and Nmb735 as the 
positive control for protection. Most assays were repeated three to five times in separate 
experiments to assess the repeatability of the assay.  
By contrast to 44/76-SL strain, the Cu385 strain proved to be poorly virulent in infant rats. 
Even with the highest challenge dose of 8×107 cfu/pup tested, no reproducible infection could 
be obtained. Thus modified growth methods (early-log, mid-log, late-log, and stationary 
phase, broth-grown bacteria) were tested to increase its virulence. As the results were not 
satisfactory, several additional invasive disease isolates of the same phenotype (B:4:P1.19,15) 
and a Cuban vaccine strain, previously received from another source (FDA), were tested. 
Finally, the four-times rat-passaged Cu385 received from FDA was found adequately virulent 
and chosen as the challenge strain. For a bacterial challenge a dose of approximately 106
cfu/pup was chosen as the lowest dose giving satisfactory development of bacteremia with the 
Cu385 strain. A similar challenge dose was selected for strain 44/76-SL. 
5.3.2 Strain characterization 
The expression of different OM components and capsular PS in un-passaged strains used in 
SBA assays and rat-passaged strains used in IRPA assays was studied by SDS-gels and 
whole-cell EIAs. In strain 44/76-SL, no effect of rat-passage on expression profiles was 
detected (III; Table 2). The Cu385 strain used in IRPA assays differed from that used in SBA 
assays (Perkins et al. 1998) in two ways. First, it expressed more OpcA protein. Second, it 
had lost L8 after rat-passage.  
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5.3.3 Vaccine responses against strain 44/76-SL 
As compared to the results from 4-fold rises in anti-OMV IgG levels and to a lesser extent 
also in SBA titers, the numbers of vaccine responders in IRPA assay were only modest (II; 
Table 4).  
Altogether 46% (42/92) of the pre-vaccination sera were IRPA positive (PI ?10) with strain 
44/76-SL (II; Table 3), compared with 50% (46/92) in the SBA assay (titer ?4). Six weeks 
after the second dose, 51% (19/37) of the sera from the Norwegian and 40% (14/35) from the 
Cuban vaccine recipients were IRPA positive (II; Table 3). Twenty-two percent (8/37) of the 
Norwegian and 11% (4/35) of the Cuban vaccine recipients had responded in IRPA assay, 
compared with 65% (24/37; P<0.05) and 37% (13/35; P<0.05) in SBA assay, and 81% 
(30/37; P<0.05) and 11% (4/35) in EIA measuring anti-OMV IgG antibodies (II; Table 4). In 
neither of the two OMV vaccine groups was the proportion of IRPA responders significantly 
higher compared to the controls (II; Table 3). GM PI increased by 1.9-fold in the Norwegian 
and by 1.4-fold in the Cuban vaccine recipients (II; Table 3); in neither group was the 
difference between pre- and post-vaccination PIs statistically significant. In the control group, 
15% (3/20) of the vaccinees showed an IRPA response compared to none in SBA assay or 
EIA, but the number of IRPA positive sera and the GM PI showed a slight, non-significant 
decrease. 
5.3.4 Vaccine responses against strain Cu385 
Altogether 12% (11/92) of the pre-vaccination sera were IRPA positive with strain Cu385 (II; 
Table 3), compared 34% (31/92; P<0.05) in SBA assay. Six weeks after the second dose, 49% 
(18/37) of the sera from the Norwegian and 26% (9/35) from the Cuban vaccine group were 
IRPA positive (II; Table 3). Thirty percent (11/37) of the Norwegian and 14% (5/35) of the 
Cuban vaccine recipients had responded in IRPA assay, compared to 35% (13/37) and 29% 
(10/35) in SBA assay, and 51% (19/37; P<0.05) and 59% (20/34; P<0.05) in EIA. In the 
Norwegian OMV vaccine group the proportion of IRPA responders was significantly higher 
compared to the control group (II; Table 3). GM PI increased 3.5 and 2.2-fold in the 
recipients of the Norwegian and Cuban vaccines, respectively (II; Table 3); in both groups the 
difference between pre- and post-vaccination PIs was statistically significant (P<0.05). None 
of the control vaccinees showed a response in IRPA or SBA assay.  
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5.3.5 Effect of pre-vaccination IRPA on detection of responses 
To study whether PI of the pre-vaccination sera affected the detection of vaccine responders 
in general, the IRPA data were analyzed also separately for the recipients of the Norwegian 
and Cuban vaccines who were IRPA negative (PI < 10) at the time of enrollment. With both 
strains, the results were similar to those for all vaccines, implying that pre-vaccination IRPA 
activity did not measurably hinder the detection of vaccine responses. 
5.3.6 Correlation of IRPA, SBA, and anti-OMV IgG levels: pre-vaccination sera 
For both strains, there was a statistically significant positive correlation between SBA titers 
and anti-OMV IgG levels (II; Fig. 2A and 2B). The correlation coefficients between PI and 
anti-OMV IgG levels (II; Fig. 2C and 2D) or PI and SBA titers (II; Figures 2E and 2F), were 
noticeably lower and significant only for the strain Cu385.  
On the average, SBA titers were significantly higher in IRPA-positive (PI ≥10) than in IRPA-
negative (PI < 10) sera (II; Fig. 2E and 2F). However, 43% (18/42) of the sera positive with 
strain 44/76-SL had SBA titers <4 and one third (14/42) had titers < 2 (II; Fig. 2E). Only 11 
pre-vaccination sera were IRPA positive against strain Cu385, but the respective proportions 
were similar: 45% (5/11) of the IRPA positive sera had SBA tires <4 and 27% (3/11) had 
titers <2 (II; Fig. 2F). On the other hand, 48% (22/46) and 81% (25/31) of the sera with SBA 
titer of ≥4 against 44/76-SL and Cu385 strains, respectively, were IRPA negative (II; Fig. 2E 
and 2F). Thus, while the GM SBA titers were significantly higher among the IRPA positive 
than the IRPA negative pre-vaccination sera, many individual samples were IRPA positive 
with strain 44/76-SL without having bactericidal activity (SBA titer <4), and vice versa.
5.3.7 Correlations of IRPA, SBA, and anti-OMV IgG levels: post-vaccination sera 
Similar to the pre-vaccination sera, for both OMV vaccine groups there was a statistically 
significant positive correlation between SBA titers and anti-OMV IgG levels with strain 
44/76-SL (II; Fig. 3A and 3B), and a moderate correlation with strain Cu385 (II; Fig. 4A and 
4B). The correlation coefficients between PIs and anti-OMV IgG levels (II; Fig. 3C, 3D, 4C 
and 4D) or PIs and SBA titers (II; Fig. 3E, 3F, 4E and 4F) were lower but in most cases 
statistically significant and with the homologous strains, higher than the corresponding pre-
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vaccination values, indicating a vaccine response. Despite the vaccine-induced increase in 
correlation coefficients with the homologous target strains, a significant portion of the SBA 
positive sera (SBA titer ?4) remained IRPA negative (PI<10). 
To conclude, as compared to 4-four fold rises in anti-OMV IgG and also in SBA titers, the 
sensitivity of IRPA assay to detect vaccine responders was generally only modest. With pre-
vaccination sera, similar numbers of positive sera were detected in IRPA and SBA assays 
with strain 44/76-SL (46% versus 50%), while with strain Cu385 the sensitivity of the IRPA 
assay was less than the SBA assay (12% positive in IRPA assay compared to 34% in SBA 
assay). The correlation between IRPA PIs and SBA titers (or anti-OMV IgG concentrations) 
with strain 44/76-SL was only modest. A significant portion of IRPA positive pre-vaccination 
lacked SBA (43%; 18/42), and vice versa (48%; 22/46). 
5.4 Specificity of natural antibodies conferring IRPA (III) 
A significant proportion of IRPA positive pre-vaccination sera with strain 44/76-SL lacked 
SBA and vice versa (II). Thus, our next aim was to assess the specificity and functional 
activity of natural antibodies responsible for IRPA with 44/76-SL strain, especially among 
IRPA positive but SBA negative sera. To this end, four subsets of pre-vaccination sera (6-7 
sera/subset) of Icelandic teenagers with convergent or discrepant SBA and IRPA results 
(Table 3) were analyzed for total, specific and functional antibodies by EIA, immunoblotting, 
IgG quantitation against live meningococcal cells by flow cytometry and OPA assay. Normal 
human sera (NHS), collected from healthy Finnish children of different ages, were used to 
verify the findings obtained with Icelandic study sera and a rat strain C6 deficient 
complement to assess the importance of complement-mediated bacterial lysis for protection. 
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5.4.1 IgG to OMVs 
The OMV IgG EIA data of the Icelandic pre-vaccination sera resembled closely the data 
obtained by SBA assay: no significant differences in anti-OMV IgG concentrations between 
IRPA positive, SBA positive category I and IRPA negative, SBA positive category II sera, or 
IRPA positive, SBA negative category III and IRPA negative, SBA negative category IV sera 
were found (Table 3). Highest IgG levels were found for category I. Category II sera showed 
similar, albeit approximately 1.7-fold lower levels than category I sera while SBA negative 
category III and IV sera showed negligible IgG levels. 
5.4.2 OPA
To find out whether other mechanisms than SBA might be responsible for protection of 
Icelandic sera in IRPA, OPA of the sera was evaluated with PMNL as effector cells and live 
44/76-SL cells as the target. Again, the results were similar to those obtained with SBA assay 
(Table 3, III; Fig. 1c) with no significant differences between categories I and II, or III and 
IV, respectively. 
5.4.3 IgG to viable meningococci  
IgG antibody binding to live 44/76-SL bacteria was determined by flow cytometry. Again, the 
results were similar to those obtained with the SBA assay (Table 3, III; Fig. 1d). No 
significant differences in antibody levels between IRPA positive and IRPA negative category 
I and II sera, or category III and IV sera, were found. 
5.4.4 Antibody specificity on immunoblots 
The possible association between antibody specificity and IRPA was analyzed by blotting the 
sera against OMV from strain 44/76-SL followed by evaluation of the IgG binding intensity 
to several outer membrane components. Most sera (19/26, 73%) showed medium or strong 
signals to one or more of the antigens. Although large individual variations in the antibody 
specificities were observed, all sera in category I and II (n=12) demonstrated such signals, 
thus roughly resembling the findings of SBA and IgG levels. Among the 14 SBA negative 
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sera in category III and IV, only one serum showed strong signals, six gave medium signals 
and the remaining seven sera no or negligible signals. No differences in the antigen binding 
patterns between IRPA positive and IRPA negative category I and II sera, or category III and 
IV sera were detected that could account for a specific protective activity. 
5.4.5 IgG and IgM antibody to serogroup B capsular polysaccharide 
As antibodies against capsular polysaccharide cannot be detected by immunoblots, B-PS 
specific IgG and IgM antibodies were measured by EIA. With the exception of three 
individual sera with titers > 1,000 (one individual in category I and 2 individuals in category 
II), the IgG titers to B-PS were very low in all categories (GM IgG titer range 36-127), with 
15/26 (58%) of the sera having a titer ?100 and 22/26 (85%) a titer ? 200. No significant 
differences in titers between IRPA positive and IRPA negative category I and II sera, or 
category III and IV sera that could explain protection were found (Table 3, III; Fig. 1e). In 
contrast, IgM titers to B-PS were significantly (P=0.006) higher among the IRPA positive, 
SBA positive than the IRPA negative, SBA positive category, and among the IRPA positive, 
SBA negative category than the IRPA negative, SBA negative category (P=0.013) (Table 3, 
III; Fig. 1f). No significant differences in IgM titers between SBA positive and negative sera 
were found. 
5.4.6 Correlation of IRPA and in vitro antibody measurements against strain 44/76 
To confirm the importance B-PS IgM antibodies for protection, the results of functional and 
quantitative antibody measurements were subjected to correlation analysis. Only IgM 
antibody to group B capsular polysaccharide (B-PS) correlated positively (r=0.76, P<0.001) 
with IRPA against strain 44/76-SL (III; Fig. 2f). Studies with NHS collected from Finnish 
children of different ages (7, 14, and 20 months, and 10 years) confirmed this finding (III; 
Fig. 4) and showed a clear, age-related increase in B-PS specific IgM antibody that coincided 
with age-related increase in PI (III; Fig. 3).  
5.4.7 Assessment of IRPA in complement component C6-deficient rats 
To confirm further the importance of B-PS specific IgM antibody to protection against strain 
44/76-SL, two IRPA positive NHS from 10 year-old Finnish children were absorbed with 
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aluminum hydroxide gel-bound B-PS (Al-B-PS) and the non-absorbed and absorbed sera 
assayed for IRPA after verification of anti-B-PS IgM depletion. To assess whether protection 
afforded by these sera was independent on direct bacterial lysis, as suggested by the lack of 
SBA using human or infant rat serum as the complement source, a rat strain with a deficiency 
in the terminal part of the complement pathway (C6-deficiency), i.e. in the generation of the 
membrane attack complex, was used.  
The non-absorbed sera were equally protective in both rat strains. As expected, absorption 
with Al-C-PS did not reduce protective activity. This was in contrast to absorption with Al-B-
PS that completely abolished protective activity. (III; Fig. 5).  
To conclude, these results strongly suggested that the IRPA conferred by non-immune sera 
against serogroup B 44/76-SL meningococci was mainly mediated by anti-B-PS IgM 
antibody. The protection seemed independent of direct bacterial lysis as evident from the lack 
of SBA in vitro and equal protective activity of NHS in complement sufficient and C6 
deficient animals. 
5.5 Importance of antibody specificity, isotype and complement-mediated 
bacterial lysis on protection (IV) 
As stated above, in sera from un-immunized individuals IRPA against 44/76-SL strain was 
mainly mediated anti-capsular IgM antibodies. To verify that antibodies of human origin to 
non-capsular antigens are in general able to confer passive protection in the infant rats, and to 
study the effect of antibody specificity and isotype to protection in more detail, the parental 
mouse P1.16 PorA specific mIgG2a Mab (Jiskoot et al. 1991), the human IgG1-4 isotypes 
derived from it (Vidarsson et al. 2001), and a monoclonal mouse IgG2a Mab with specificity 
to B-PS (Nmb735 (Frosch et al. 1985)) were studied for IRPA. Like in the previous study 
(III), C6 deficient rats were used to assess the importance of complement mediated lysis on 
protection.
5.5.1 Bactericidal activity (BA)  
The BA of the Mabs was first reassessed using human and infant rat serum collected from 
HsdBrlHan:WIST rats as the exogenous complement source. As previously, the B-PS specific 
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Nmb735 and the parental PorA specific mouse IgG2a were the most potent antibodies in this 
assay, followed by human IgG isotypes in the order of activity of IgG1=IgG3>IgG2; the IgG4 
failed to show any bactericidal activity at the concentrations up to 20 ?g/ml tested (Table 4, 
IV; Table). Approximately 3-fold higher Mab concentrations were needed for BA (? 90% 
killing of the inoculum) with human compared rat complement but this difference did not 
reach statistical significance (P=0.06, paired one-sided t-test).  
5.5.2 IRPA assays with complement sufficient rats 
Similar to our previous studies (I and (Toropainen et al. 2001)), the B-PS specific Mab 
Nmb735 (IV; Fig 1a) and the parental PorA specific mouse IgG2a (mIgG2a, IV; Fig. 1b) 
were highly protective in complement sufficient rats. The lowest dose of 0.02μg/pup of the 
former and 0.5μg/pup of the latter reduced blood bacterial counts in HsdBrlHan:WIST rats 
significantly as compared to control animals receiving saline (Table 4). As compared parental 
PorA specific mIgG2a, the human IgG1 (Table 4, IV; Fig. 1c) and IgG3 (Table 4, IV; Fig. 1e) 
exhibited approximately similar activity while a 4-fold higher antibody dose (2 compared to 
0.5 μg/pup) of IgG2 was needed for equal protective activity (Table 4, IV; Fig 1d). The non-
bactericidal human IgG4 (Table 4, IV; Fig. 1f) failed to show significant protective activity at 
any antibody doses up to 20 μg/pup tested.   
Table 4. Bactericidal and infant rat protective activities of monoclonal antibodies (Mab). 
 90% killing* Passive protection**
Mab Human  
complement
Infant rat  
complement
HsdBrlHan:WIST PVG/c+ PVG/c- 
Nmb735 0.08 0.027 0.02  0.02 0.02 
mIgG2a 0.08 0.027 0.5  0.5 5.0 
hIgG1 0.74 0.25 0.5 5.0 >20 
hIgG2 2.2 0.74 2.0 ND >20 
hIgG3 0.74 0.25 0.5 ND >20 
hIgG4 >20 >20 >20 ND >20 
* Lowest antibody concentration (μg/ml) needed for ?90% killing of the 44/76-SL 
(B:15:P1.7,16) bacteria in the presence of human or infant rat (HsdBrlHan:WIST) 
complement. 
** Lowest antibody dose needed for passive protection in the infant rats against challenge 
with approximately 106 cfu of 44/76-SL bacteria. Protection was defined as a significant 
(P<0.05) reduction in geometric mean bacteremia level (cfu/ml blood) compared to control 
animals given saline. 
ND, not determined. 
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Due to difficulties of the breeder to supply us with complement sufficient partner (PVG/c+) 
for the C6 deficient rat strain, only the B-PS specific Mab Nmb735, the parental PorA 
specific mIgG2a, and the human IgG1 isotype could be tested in this rat strain. With the B-PS 
and PorA specific mouse IgG2a Mabs, similar results were obtained in both complement 
sufficient rat strains (Tabel 4, IV; Fig. 1a and 1b). This was in contrast to the PorA specific 
human IgG1 isotype of which a 10-fold higher antibody dose (5 versus 0.5 μg/pup) was 
needed for equal protection in PVG/c+ compared to HsdBrlHan:WIST rats (Table 4, IV; Fig. 
1c). To study the possibility that rat strain specific differences in complement activity might 
have explained the lower protective activity of the human IgG1 in PVG/c+ compared to 
HsdBrlHan:WIST rats, the in vitro BAs of the parental PorA specific mIgG2a and the human 
IgG1 isotype were reassessed using pooled serum from either rat strain as the exogenous 
complement source. No rat strain specific differences in the lytic activity were detected. 
5.5.3 IRPA assays with complement component C6 deficient rats 
Of the PorA specific antibodies (Table 4, IV;Figs 1b-f), only the parental mIgG2a (Fig 1b) 
conferred protection in C6 deficient PVG/c- animals, requiring a 10-fold higher antibody dose 
(5 versus 0.5 μg/pup) for protection as compared to complement sufficient HsdBrlHan:WIST 
or PVG/c+ animals. This was in contrast to anti-B-PS antibody NmB735 was equally 
protective in all rat strains (Table 4, IV; Fig 1a).  
To conclude, the PorA specific parental mouse IgG2a and the human IgG1-3 isotypes all 
induced efficient bactericidal activity in vitro in the presence of human or infant rat 
complement and augmented bacterial clearance in complement sufficient animals while the 
IgG4 was unable to. In C6 deficient animals augmentation of bacterial clearance by anti-PorA 
antibodies was severely impaired, suggesting that protection afforded anti-PorA antibody was 
mainly dependent on the activation of the whole complement pathway and subsequent 
bacterial lysis. This was in contrast to anti-B-PS antibody NmB735 that was equally 
protective in all rat strains, confirming our previous findings with natural IgM anti-capsular 
antibodies of human origin (III). 
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6 DISCUSSION 
6.1 Methodological and study design aspects 
The development of serogroup B meningococcal vaccines has been hampered by the lack of a 
reliable animal model for predicting their protective efficacy. Although passive protection in 
animal models has been widely used to evaluate the protective activity of monoclonal 
antibodies or immune sera raised in experimental animals, no attempts have been made to 
study their applicability and validity to assess vaccine responses using human sera. 
The purpose of this thesis that includes four consecutive studies (I-IV) was twofold. First, we 
wanted to evaluate the applicability of the infant rat protection assay to assess natural and 
serogroup B outer OMV vaccine induced immunity in humans against N. meningitidis
serogroup B in general. To this end, after careful adaptation of the assay for use with human 
sera (I), pre- and post-vaccination serum samples from teenagers immunized either of the 
current two efficacious meningococcal serogroup B OMV vaccines (Bjune et al. 1991b, 
Sierra et al. 1991) during a previous immunogenicity trial in Iceland (Perkins et al. 1998) 
were analyzed for IRPA (II), and the results compared to SBA data obtained with the same 
serum set (Perkins et al. 1998). This comparison was necessary, as the SBA assay has been 
regarded as the “gold standard” surrogate of protection also against disease caused by 
serogroup B meningococci (Holst et al. 2003). Second, we wanted to look more closely the 
specificity and functional activity of antibodies conferring protection in this model. In these 
studies, two approaches were used. First, the specificity of antibodies conferring protection in 
Icelandic study pre-vaccination sera was determined (III). Second, the protective activity 
well-characterized Mabs of different specificity or antibody isotype was studied (IV). In the 
last two studies, complement component C6 deficient animals were used to evaluate the 
importance of complement-mediated bacterial lysis in protection.  
In the adaptation of the IRPA assay for use with human sera (I), four human sera were used. 
Three of them were collected after immunization of adult volunteers with the Norwegian 
meningococcal serogroup B OMV vaccine (Bjune et al. 1991b) and one was normal human 
serum from an unvaccinated individual with no history of meningococcal disease 
(representing pre-vaccination serum). These sera were selected from a large panel of sera 
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available at NIPH on the basis of differences in their antibody profiles measured by 
immunoblotting and functional activities (SBA and OPA) measured in vitro. Because one of 
the main aims of this study was to examine the reproducibility of the assay by repeating the 
same assay (same serum dilution, same challenge dose) on several days, for practical and 
ethical reasons, concerning the use of experimental animals, the number of sera assayed in 
this study was restricted to four. Thus, the effect of antibody specificity as well functional 
activity on protection could not be reliably addressed. 
To evaluate the applicability of the IRPA assay to detect serogroup B OMV vaccine responses 
in humans, pre- and post-vaccination serum samples from 92 teenagers, representing a 25% 
subset of sera from subjects who had received two doses of either the Norwegian OMV 
vaccine based on strain 44/76-SL (B:15:P1.7,16) (Fredriksen et al. 1991), the Cuban OMV 
vaccine based on strain Cu385 (B:4:P1.19,15) (Sierra et al. 1991), or the serogroup A/C 
capsular PS control vaccine during a previous immunogenicity trial in Iceland (Perkins et al.
1998), were used (II). Concerning the use of experimental animals, testing of larger number 
of sera was considered neither ethically justifiable nor practical. Due to stratified sample 
selection (25% sample drawn from vaccine-responders as well as non-responders), the 
percentages of SBA responders reported in the original study (Perkins et al. 1998) were 
roughly retained in the present serum subset (II; Table 1). Samples taken after the second dose 
were selected for this study because the efficacy trials with these vaccines had been 
performed with a two-dose schedule (Bjune et al. 1991b, Sierra et al. 1991) and because in 
the original study plan comparison of IRPA data with available efficacy data was also 
included, even though the latter data was obtained from different study populations (Bjune et 
al. 1991b, Sierra et al. 1991).  
In study III, a representative set (26/92; 28%) of pre-vaccination sera from Icelandic teenagers 
(Perkins et al. 1998) with convergent or divergent IRPA and SBA data (II) against strain 
44/76-SL was used to characterize the specificity and functional activity of natural antibodies 
conferring IRPA with strain 44/76-SL. The sera for this study were selected on the basis of 
pre-existing IRPA (II) and SBA data (Perkins et al. 1998) and the availability of adequate (> 
0.2-ml) volumes. NHS (n=20) collected from healthy Finnish children of different ages (7, 14 
and 24 months, and 10 years) were used to verify the findings obtained with sera from 
Icelandic teenagers and to assess the development of IRPA. These sera had been collected in 
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connection with previous immunogenicity studies (Mäkelä et al. 2003) and were randomly 
selected from samples available at KTL.  
In study IV, a mouse P1.16 PorA specific mIgG2a Mab (Jiskoot et al. 1991), the human 
IgG1-4 isotypes derived from it (Vidarsson et al. 2001), and a monoclonal mouse IgG2a Mab 
with specificity to B-PS (Nmb735 (Frosch et al. 1985)) were used as model antibodies to 
assess the effect of antibody specificity (sub-capsular versus capsular antigen), antibody 
isotype (human IgG1-4), and the importance of complement-mediated bacterial lysis on 
protection. These Mabs were selected on the basis of their availability, which for the PorA 
protein well reflects the general interest and importance of this antigen as vaccine candidate 
against serogroup B meningococcal disease (Muttilainen et al. 1995, Claassen et al. 1996, 
Idänpään-Heikkilä et al. 1996, Christodoulides et al. 1998). In the original study plan, testing 
of class-switched B-PS specific IgG1 and IgM Mabs of human origin (Raff et al. 1988, Raff
et al. 1991) was also included but due to their poor availability, this plan could not be 
executed.  
For a bacterial challenge strain to adapt the IRPA assay for use with human sera (I) we chose 
strain IH5341, a CSF isolate from a patient with invasive meningococcal disease (Käyhty et 
al. 1989). This strain, phenotypically homologous (B:15:P1.7,16) to the clone that had in the 
past decades caused long-drawn epidemics in Northern Europe (Poolman et al. 1986), was 
chosen for a challenge strain largely based on our previous experience on it in this model 
(Nurminen et al. 1992, Idänpään-Heikkilä et al. 1995). It was also homologous to the strain 
44/76, from which the vaccine that the donors of the human post-vaccination sera received 
was made. 
In studies with the Icelandic study sera (II, III) and Mabs (IV), the Norwegian vaccine (44/76-
SL; B:15:P1.7,16) and the Cuban vaccine (Cu385; B:4:P1.19,15) strains were used. As one of 
our aims was to compare the IRPA data with SBA data (II), a natural choice for the challenge 
strains used in IRPA studies would have been the exactly same strains that had previously 
been used to generate the SBA data (Perkins et al. 1998). Unfortunately, this was not possible 
for the Cu385 strain due to poor reproducibility of bacteremia, and the Cu385 received from 
another source was considered the best choice. As expected, this strain was phenotypically 
similar to the strain received from CDC and used in their SBA assay except for a higher 
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expression level of the outer membrane OpcA protein and the loss of L8 expression after rat-
passage (II; Table 2). Due to these differences, the results of IRPA and SBA assays were not 
entirely comparable. Both the Norwegian and the Cuban OMV vaccine lots administered in 
the Icelandic trial contained the OpcA protein (Griffiths et al. 1994).  
In passive protection studies rat-passaged strains were used. Criticism has been raised over 
this procedure (Gorringe et al. 2001) as it presumably selects meningococcal variants better 
adapted to the animals and hence, in theory, moves the animal model one step away from the 
human disease. We have however found this procedure useful to increase the repeatability of 
the IRPA assay, which is of utmost importance for large-scale passive protection studies. 
While mechanisms for increased repeatability of infection after rat-passage are not fully 
understood, it is probably due to more homogenous inoculum. Interestingly, similar to 
previous studies in an intranasal mouse model of meningococcal infection (Mackinnon et al.
1993), in the Cu385 strain a switch from L3,7,8 immunotype to L3,7 immunotype after rat-
passage was detected (II; Table 2), confirming the importance of LOS IT as a virulence 
determinant (Jones et al. 1992). In the 44/76-SL strain, lacking L8 expression already before 
rat-passages, no change in antigen expression after rat-passage was detected. 
For a bacterial challenge dose with the Icelandic sera (II, III), a dose of approximately 106
cfu/pup was selected as the lowest dose giving reproducible bacteremia with the Cuban 
vaccine strain Cu385. For consistency, a similar challenge dose was selected for strain 44/76-
SL even though our previous results (I) suggested that this might somewhat decrease IRPA 
assay sensitivity.  
In IRPA studies with Icelandic study sera (II, III), a PI of 10, equivalent to one-log reduction 
in GM blood bacterial density in an experimental group of animals (n=6), and at least 10-fold 
rise in PI of paired sera were used as end-points. With the intra- and inter-assay CVs of 
approximately 20%, a lower threshold was considered inappropriate. The IRPA data were 
analyzed by several different approaches, including comparison of responder percentages, 
GM PIs and the proportion of vaccinees achieving a threshold PI of 10. A 10-fold rise in PI 
was also analyzed separately for study participants without detectable IRPA activity (PI < 10) 
at study enrolment. In general, all methods gave similar results.  
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Similarly to previous studies (Goldschneider et al. 1969a, Milagres et al. 1994, Holst et al.
2003, Welsch and Granoff 2004), in SBA assays a titer of 4 was used as the threshold of 
protection. Although a threshold SBA titer that would predict protection against 
meningococcal disease at an individual level has not yet been established and will apparently 
be difficult if not impossible to define, it has been suggested that at population level this 
threshold correlates well with the Norwegian serogroup B OMV vaccine efficacy (Holst et al.
2003).   
It is well recognized that the use of complement from heterologous species (especially 
rabbits) may greatly enhance the SBA of meningococcal anti-PS antibodies compared to their 
activity with human complement (Griffiss and Goroff 1983, Zollinger and Mandrell 1983, 
Mandrell et al. 1995). Thus, to avoid mistaken conclusions about the protective activity of 
human antibodies measured in vivo in the presence of rat complement (and phagocytes) 
compared to SBA measured in vitro in the presence of human complement (II, III), we used 
both human and infant rat serum as the exogenous complement source in bactericidal assays
in vitro with NHS (III) and mouse-human chimeric Mabs (IV). Similar activities were found 
with both complements, suggesting that the discrepancies between IRPA and SBA data (II, 
III) were not due to species-specific differences in the efficiency of complement to lyse 
antibody-targeted bacterial cells. 
To find out whether OPA might had explained protection in IRPA positive but SBA negative 
sera, the OPA of the Icelandic study sera was evaluated as respiratory burst by flow cytometry 
using human PMNLs as effector cells and live 44/76-SL bacteria as the target cells (III). 
PMNLs of human origin were used because we wanted to compare IRPA assay with a 
previously established and standardized OPA assay (Aase et al. 1998) and because it would 
have been very difficult to obtain sufficient amount of PMNLs from infant rats due to their 
small size.
6.2 Adaptation of IRPA assay for use with human sera (I) 
An important question for vaccine development was whether the IRPA assay could be used to 
test the protective activity conferred by human immune sera and thus possibly as a surrogate 
assay for vaccine efficacy. Such a use would, however, need careful choice of the assay 
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conditions for sensitivity and repeatability, with the additional need arising from ethical 
considerations of the use of experimental animals to keep the number of animals needed 
small. Therefore, the aim of our first study was the adaptation and standardization of the 
infant rat infection model for use with human sera. 
From previous studies (Saukkonen 1988) we knew that a high challenge dose will lead to a 
predictable and consistent development of bacteremia and meningitis; on the other hand, in 
protection assays it is usually easier to prevent an infection caused by a small rather than a 
large challenge dose. Therefore, in preliminary studies several challenge doses of strain 
IH5341 were tested, aiming at reproducible infection and sensitive detection of protection 
with little inter-assay variability. For ethical reasons, early sampling, before the animals get 
very ill, was desirable. In previous passive protection studies an observation period of six 
hours after challenge had been used with good results (Saukkonen et al. 1989, Nurminen et al.
1992). Considering that a longer time of observation might allow the use of a smaller 
challenge dose and consequently possibly increase the sensitivity of the protection assay 
(Harris et al. 2003a, Harris et al. 2003b), we also assessed the outcome 24 hours after 
challenge with the lowest dose of 104 cfu/pup. However, the results were not satisfactory, and 
six hours was chosen as the standard assay time. 
In the six-hour assay, the development of disease with doses of 105 to 107 cfu/pup was highly 
constant whether comparing the rates or the levels of bacteremia and meningitis whereas the 
lower dose of 104 was unsatisfactory in terms of consistency and predictability. Although 
lower challenge doses would probably mimic better the course of natural infection, the doses 
105 and 106 appeared more suitable for protection studies: the development of disease was 
predictable and reproducible while still allowing a reliable and sensitive detection of 
protection with a relatively low number of animals per study group (6 pups/group). 
For a potential routine test keeping the serum consumption as low as possible is desirable. 
Thus, it was good to note that 1:10 dilution gave protection; in serological surveys it would 
not be feasible to use less diluted sera since one assay, with six animals per group, will 
require a minimum volume of approximately 800 μL of the dilution, e.g. 80 μL of serum. All 
the post-vaccination sera tested were still protective at the dilution 1:30 against challenge with 
105 meningococci; the levels but more rarely the rates of bacteremia were reduced as 
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compared with controls. In contrast, dilution 1:100 gave no protection. On the basis of these 
results, a 1:10 dilution was chosen for evaluation of OMV vaccine induced IRPA assay 
responses (II). 
As expected, also the challenge dose was an important determinant of the outcome of the 
IRPA assay. Although highly protective against the lower challenge doses, the Mab Nmb735 
showed no protection against challenge with 107 meningococci. Similarly, one post-
vaccination serum that effectively protected the animals challenged with 105 bacteria failed to 
reproducibly show protection against the higher dose of 106. Thus, for passive protection 
studies the lower bacterial dose of 105 seemed more useful, providing that predictable and 
reproducible infection is obtained. 
We found the most consistent and interpretable findings when using a reduction in GM blood 
bacteremia level (cfu/ml) as the end-point of protection. Moreover, the observation that the 
rate of meningitis was dependent on the level of bacteremia also in the protection studies 
suggested that an adequate indicator of protection can be achieved by measuring the bacterial 
counts in the blood only: when the serum prevented the development of bacteremia, it also 
inhibited meningitis. 
6.3 Assay reproducibility 
Due to innate nature of infection studies in experimental animals, they are expectedly subject 
to considerable biological variability arising form the genetic variability of both the animal 
host as well as bacterial species in question. In the present studies, the reproducibility of 
IRPA assay, assessed by the development of bacteremia in saline treated control group 
animals, was found satisfactory, with coefficients of variation (CV) of approximately 15% 
(range 5-27%) for intra-assay and of approximately 20% for inter-assay comparisons. 
 To avoid bias due to uncontrolled (random) variation, a careful allotment of treatments to 
subjects at random and a strict compliance with standard assay conditions is of major 
importance. Especially, precautions should be taken to maintain the preparation of the 
bacterial inoculum (growth phase, method of dilution) and inoculation techniques as closely 
standardized as possible. To reduce the chance of differences arising due to intrinsic 
variability of the experimental animals, a high quality of animals used and their uniformity 
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with respect to age and weight are important. Although the use of genetically defined inbred 
or F1 hybrid strains of animals would further increase the uniformity of the stock and 
consequently might reduce intra- as well as inter-experimental variability, we have preferred 
commercially available outbred Wistar rats (Hsd:WU; I-III or HsdBrlHan:WIST; IV) of 
specific pathogen free-quality to inbred strains: because of their prolific breeding, large 
numbers of pups of a suitable age (4-6 days at experiment) are easily available at short notice.  
6.4 Serogroup B OMV vaccine responses in IRPA assay (II) 
To evaluate the applicability of the IRPA assay to assess serogroup B OMV vaccine 
responses, paired pre- and post-vaccination serum samples collected from young adults 
immunized with the Norwegian or the Cuban OMV vaccine during the previous 
immunogenicity trial in Iceland were used (Perkins et al. 1998). 
As discussed by Perkins et al. (Perkins et al. 1998), in the Icelandic trial the proportions of 
SBA and EIA responders among the Cuban vaccine recipients were much lower than would 
be expected from the vaccine efficacy estimate. In the present study, the proportions of IRPA 
responders were generally lower than those found in SBA and EIA with the homologous 
strains, and thus even farther from the point estimates of efficacies in the Norwegian (57%) 
and the Cuban (83%) efficacy trials (Bjune et al. 1991b, Sierra et al. 1991) (II; Table 4). 
Thus, the expectation that animal models might shed more light on the poor relationship 
between SBA activity and protection (Perkins et al. 1998) was apparently not fulfilled by our 
IRPA studies. Further, at best, the correlation between IRPA and SBA or anti-OMV IgG 
concentrations measured by EIA was only modest. Despite OMV vaccine induced increase in 
correlation between IRPA and SBA with the homologous strains, a significant portion of the 
SBA positive sera (SBA titer ?4) remained IRPA negative (PI<10). 
The bacterial challenge dose used to infect the animals is of great importance to the outcome 
of protection studies and in this study a dose of approximately 106 was used combined with 
1:10 dilution of human sera. Taking into account the lower number of vaccine responders in 
IRPA compared to SBA and EIA, the sensitivity of IRPA may not have been optimal. If the 
serum volume is not a limiting factor, use of less diluted sera, or, alternatively, a lower 
bacterial dose, as used in other studies (Welsch and Granoff 2004), might have provided 
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means for better sensitivity. In the present study, the former was not possible because of 
limited serum volumes and the latter because of the relatively low virulence of the Cu385 
strain.
Natural immunity to meningococcal disease develops with age, which, at population level, is 
associated with the prevalence of SBA (Goldschneider et al. 1969a). For serogroup A and C 
meningococci, the value of SBA as a correlate of protection is well-established. SBA has also 
been used widely as a surrogate marker for protective immunity and vaccine efficacy against 
serogroup B disease, although the relevant antigens have been thought to be protein rather 
than polysaccharide by nature (Zollinger and Mandrell 1983, Williams et al. 2003).  It was 
therefore of interest to compare the protection measured by IRPA with SBA. An interesting 
finding relevant to the recently suggested use of a mean SBA titer of 4, as the threshold 
predicting protection against invasive serogroup B disease (Holst et al. 2003), was that 
although SBA correlated to some extent with IRPA, many individual samples, especially 
among the pre-vaccination sera, were strongly protective with strain 44/76-SL without having 
bactericidal activity (SBA titer <4), and vice versa. This is in accordance with the recently 
published IRPA study with serogroup C meningococci showing that naturally acquired anti-
capsular antibodies against serogroup C meningococci can confer protection in the infant rats 
even in the absence of measurable SBA (Welsch and Granoff 2004).  
An important question that remains to be solved is why a significant portion of the SBA 
positive (titer ?4) pre-vaccination sera (48% for strain 44/76-SL, 81% for Cu385) compared 
to only 11% for the serogroup C strain in the study by Welsch and Granoff (Welsch and 
Granoff 2004) failed to show protection in IRPA. Besides intrinsic differences between the 
strains, the reason could also lie in the intrinsic differences between these two IRPAs, 
especially in the serum dilution (1:4 compared 1:10 in our study) and the bacterial challenge 
dose (0.8-1.4×103 compared 1.7-9.3×106 in our study) used. Unfortunately, insufficient 
volumes of the Icelandic sera prevented further testing of these parameters. 
To conclude, although likely to be useful for the pre-clinical evaluation of candidate MenB 
vaccines (Saukkonen et al. 1987, Saukkonen et al. 1989, Idänpään-Heikkilä et al. 1995, 
Welsch et al. 2003, Welsch et al. 2004) and natural immunity (Welsch and Granoff 2004), the 
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IRPA, as described herein, seemed less suitable for large-scale evaluation of serogroup B 
OMV vaccine responses in clinical samples.  
6.5 Specificity of natural antibodies conferring IRPA (III) 
In the search for vaccine candidates, natural immunity to serogroup B meningococcus has 
been less studied. Thus, we evaluated pre-vaccination sera from Icelandic teenagers with 
convergent or discrepant SBA and IRPA data with 44/76-SL strain for specific and functional 
antibodies and could clearly show that natural IgM antibodies to B-PS are able to confer 
protection against serogroup B disease in an infant rat model of meningococcal infection. 
Studies with normal human sera from healthy Finnish children of different ages (7, 14 and 24 
months, 10 years) confirmed this connection. This finding is in contrast with the general 
conception of the minor importance of B-PS specific antibodies for protection against 
serogroup B meningococcal disease. Due to the low avidity, especially of IgG (Mandrell and 
Zollinger 1982), and the poor bactericidal activity of B-PS specific antibodies in SBA assays 
with human complement (Zollinger and Mandrell 1983), their role in protection against 
meningococcal infection has been challenged. 
Interestingly, the protection afforded by B-PS specific IgM seemed to be independent of 
direct lysis of the bacteria, as demonstrated by the inability of the half of the IRPA positive 
Icelandic sera and the majority (13/14) of the Finnish NHS to promote in vitro bacterial 
killing in the SBA assay (titer <4). This finding was not an artifact arising from intrinsic 
differences in the ability of rat compared to human complement to augment bactericidal 
activity of anti-B-PS antibodies as similar, negligible in vitro bactericidal activities in NHS 
were obtained with both complements. In support of these findings, the NHS showed equal 
protective activity in a complement-sufficient rat strain and in a rat strain with a deficiency 
(C6 deficiency) in the generation of the membrane attack complex.  
Somewhat surprisingly, OPAs with human PMNLs as the effector cells did not, however, 
explain the protective activity of the IRPA positive but SBA negative Icelandic sera as 5/7 
(71%) of these sera were also OPA negative (titers < 2). Thus, the mechanism of protection 
conferred by B-PS specific antibodies remain to be fully evaluated. Possibly, in the infant 
rats, the macrophages of the mononuclear phagocyte system (Frasch et al. 1976) rather than 
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PMNLs might have been responsible for bacterial clearance. It is well recognized that Fc and 
especially C3 receptors on macrophages play a crucial role in the clearance of other well-
opsonized encapsulated bacteria from the bloodstream (Rogers 1960, Brown et al. 1983a, 
Bohnsack and Brown 1986, Pelkonen and Pluschke 1989, Noel et al. 1990).  
With NHS from Finnish children, a clear age-related increase in B-PS specific IgM antibodies 
was found that closely coincided with the development of IRPA. The origin of anti-B-PS IgM 
antibody remains open but could be due to carriage of non-virulent serogroup B bacteria or 
cross-reactive bacteria from other genera, such as E. coli K1 or Moraxella nonliquefaciens.
All these three species share an immunochemically identical polysialic acid capsular 
polysaccharide (Bøvre et al. 1983, Devi et al. 1991).  
6.6 Importance of antibody specificity, isotype and complement-mediated 
bacterial lysis on protection (IV) 
While there is evidence supporting the importance of both antibody mediated BA 
(Goldschneider et al. 1969a, Goldschneider et al. 1969b) and opsonophagocytosis (Ross et al.
1987) for protection against serogroup B meningococcal disease, due heterogeneity of 
antibody responses following disease or serogroup B OMV vaccination with respect to both 
antibody specificity and subclasses, their relative contribution to protective immunity has 
been difficult to be delineated. In this study, we addressed this question by assessing the 
protective activity of the parental mouse P1.16 PorA specific mIgG2a Mab (Jiskoot et al.
1991), the four human IgG isotypes (IgG1-4) derived from it (Vidarsson et al. 2001), and a 
monoclonal mouse IgG2a Mab with specificity to B-PS (Nmb735 (Frosch et al. 1985)) in 
complement sufficient and C6 deficient (Leenaerts et al. 1994) infant rats.  
Our results showed clearly that while the parental PorA specific mouse IgG2a and the human 
IgG1-3 isotypes derived from it efficiently enhanced bactericidal activity in vitro and 
augmented bacterial clearance in vivo in complement sufficient animals, in C6 deficient 
animals the augmentation of bacterial clearance was severely impaired. This was in contrast 
to a bactericidal, B-PS specific mouse IgG2a antibody that conferred similar protective 
activity irrespective of the rat strain used, thus confirming our previous findings with non-
bactericidal B-PS specific IgM antibody of human origin (III).  
89
Why antibody to meningococcal capsular compared to sub-capsular antigen is more efficient 
in conferring protection in C6 deficient animals and also opsonophagocytosis in vitro
(Andreoni et al. 1993) is not clear but has been suggested to arise from the more superficial 
location of the anti-capsular antibody and/or C3 fragments deposited by it on bacterial surface 
(Brown et al. 1983b), where they are readily recognized by phagocytic cell FcRs and/or CRs. 
We found the relative protective activity of human IgG isotypes to be 
IgG1=IgG3>IgG2>>>IgG4 in complement sufficient HsdBrlHan:WIST rats, a result 
consistent with the in vitro bactericidal activity data in the presence of human (Vidarsson et 
al. 2001) or infant rat complement (IV) but the complete lack of protection by IgG1 and IgG3 
in C6 deficient rats being somewhat at variance with the previous phagocytic activity data 
obtained using human PMNLs as the effector cells and heat-killed 44/76-SL bacteria as the 
target or measuring respiratory burst with live bacteria (Vidarsson et al. 2001). With the 
parental mouse mIgG2a, a 10-fold higher antibody dose was needed for protection in 
complement deficient PVG/c- than the isogenic, complement sufficient PVG/c+ rat strain. 
Possibly, higher antibody doses than the 20μg/pup tested would also have been needed for the 
human IgG isotypes to confer protection in the PVG/- rat strain.  
With the B-PS specific and the parental PorA specific mouse IgG2a Mabs, similar protective 
activities were detected in both complement sufficient rat strains (HsdBrlHan:WIST and 
PVG/c+) used. This was in contrast to PorA specific human IgG1 isotype of which a ten-fold 
higher antibody dose (5.0 compared to 0.5 ?g/pup) was needed for passive protection in 
PVG/c+ compared to HsdBrlHan:WIST animals. As no rat strain specific differences were 
observed in the BA of the human IgG1 isotype using serum from HsdBrlHan:WIST or 
PVG/c+ rat as complement source, the reason for the lower protective activity of this Mab in 
PVG/c+ animals remains to be fully evaluated. Two possibilities exist to explain this 
difference between in vitro BA and in vivo protection assays. First, the sensitivity of the BA 
assay (using 20% infant rat serum as exogenous complement source) may not have been 
satisfactory to detect rat strain specific differences in complement activity. Second, there may 
be rat strain differences in the ability of rat phagocyte FcR to bind antibody of human origin. 
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7 CONCLUSIONS AND FUTURE CONSIDERATIONS 
Development of meningococcal serogroup B vaccines has been hampered by the lack of 
suitable animal models to test their protective efficacy.  In the present study, we addressed 
this question by assessing human sera taken before and after serogroup B OMV vesicle 
vaccination for protective activity in the IRPA assay, and by comparing the results with data 
obtained with previously established laboratory assays (SBA assay and EIA) and with vaccine 
efficacy data obtained earlier in different study populations. Since the specificity and the 
mechanisms of antibodies providing protective immunity are also far from resolved, we also 
looked more closely the specificity and functional activity of natural antibodies conferring 
protection in this animal model. Well-characterized Mabs were used to assess the influence of 
antibody specificity and isotype on protection, and complement component C6 deficient 
animals to evaluate the importance of complement-mediated bacterial lysis on protection.  
Although likely to be useful for the pre-clinical evaluation of candidate MenB vaccines, 
natural immunity, and assessment of mechanisms of protection, the IRPA assay, as described 
herein, is probably less suitable for large-scale evaluation of serogroup B OMV vaccine 
responses in clinical samples. First, the percentages of IRPA assay responders were much 
lower than the vaccine efficacies observed in the two large protection trials and also generally 
lower than the number of responders in the SBA assay that is widely used as “gold standard” 
assay reflecting protection. Thus, even after careful application of the method for human sera, 
the assay did not seem to serve as a robust surrogate for vaccine-induced protection. In future 
studies, efforts to more sensitive animal models are thus needed.  
Second, the IRPA assay is very laborious, time- and, most importantly, laboratory animal-
consuming. For the new generation mono- and multivalent MenB vaccines developed, 
designed to confer protection to multiple MenB strains, the number of target strains for the in
vitro and in vivo assays to evaluate their immunogenicity is likely to increase. With a serum 
set as large as in this study, this would require an enormous effort to be achieved in the IRPA 
assay.
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Third, when using IRPA assay for serogroup B OMV vaccine testing, differences in the 
virulence of test strains have to be carefully considered. In our hands, the Cuban vaccine 
strain used in the previous SBA assays was not applicable in IRPA due to poor and variable 
rate of disease the infant rats. At present, the only tools to overcome the problems of low 
virulence are to try consecutive rat-passages or, if not successful, replace the non-virulent 
strain with an acceptable virulent one. Apparently, the prerequisites of a meningococcal strain 
suitable for in vivo assays are more complicated than for in vitro SBA assays. Thus, studies 
assessing meningococcal virulence factors in animal models are desperately needed. 
Even with these limitations, the IRPA assay seemed, however, to give some additional value 
over the SBA assay in that many SBA negative pre-vaccination sera were often IRPA 
positive. Interestingly, in sera taken before vaccination, IRPA seemed to be mainly mediated 
by serogroup B capsular PS specific IgM antibodies. A clear connection between the 
acquisition of natural B-PS specific IgM antibodies and IRPA was also indicated. Even taking 
the limitations arising from the measurement of the protective activity of human antibodies in 
the presence of complement and phagocytic cells from heterologous species, our results argue 
that importance capsular PS specific antibodies on protective immunity against serogroup B 
disease may have been underestimated. Considering the typically rapid onset of invasive 
disease following infection, such antibodies could be of critical importance for protection at 
the early stages infection when antibody production to other bacterial surface structures has 
not yet efficiently started. In the future, the origin of natural B-PS specific antibodies as well 
as their mechanism of protection in the IRPA assay would be important to investigate to 
assess the relevance of these findings to protection in humans.  
The IRPA assay seemed also to possess potential to study the mechanisms how antibodies of 
different specificity afford protection. Using complement sufficient and C6 deficient rat 
strains, it was clearly shown that basic differences existed in the mechanisms how antibodies 
to sub-capsular and capsular meningococcal antigens confer protection. For the former, 
complement-mediated bacterial lysis seemed a prerequisite for protection while for the latter 
other mechanisms such as opsonophagocytosis were more likely to be involved.  
To conclude, in the future more effort should be put to study the relevance meningococcal 
infection models to assess protection afforded by antibodies of human origin in general.  
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Although the basic immunology and defense mechanisms operating in human and rodents can 
be assumed to be quite similar and in our studies no major differences in the lytic activity of 
infant rat serum compared to human serum were detected, caution should be exercised when 
interpreting results obtained from animal models to protection in humans. This could be even 
more important to take into account when dealing with microbes as strict human pathogens as 
meningococci – due to species-specific differences in innate and adaptive immunity, the 
interplay between the microbe and host can be profoundly different depending on species in 
question. Taking into consideration the importance of both complement and phagocytes for 
immunity against meningococcal disease and the variety of mechanisms that this human 
pathogen has evolved to counteract these immune mechanisms, a more careful comparison of 
the rat or mouse and human innate and adaptive immune systems is needed before the 
relevance of the current and future animal models developed to predict protection in humans 
can be established. 
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